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ABSTRACT
Cancer and cardiovascular diseases are two most fatal diseases causing
innumerable death each year. To understand the underlying mechanism of these two
diseases is really critical to assess proper therapeutic approach. Krüppel-like factor 8
(KLF8) is a member of Krüppel like family transcription factors which was found to be
upregulated in different types of cancers, primarily breast and ovarian cancer. No
studies have elucidated role of KLF8 in cardiovascular diseases till date to our
knowledge. KLF8 has been found to transcriptionally activate a host of downstream
effectors like CyclinD1, EGFR, MMP9, EPSTI1, and CXCR4 to promote cell
proliferation, cancer cell invasion and migration and transcriptionally represses Ecadherin to induce epithelial to mesenchymal transition and oncogenic transformation of
cell in multiple cancers. Our studies identified a novel posttranslational modification of
KLF8 essential for its role in promoting cancer cell migration and discovered a novel
function of KLF8 in cardiomyopathy. In our first study, we identified Serine 48 as a novel
phosphorylation site on KLF8. Pharmacological and genetic manipulations of various
potential kinases further revealed ERK2 as the responsible kinase that phosphorylates
KLF8 at S48. Functional studies indicated that this phosphorylation is crucial for
protecting KLF8 protein from degradation in the nucleus and promoting cell migration
and thereby identified this novel posttranslational modification critical for KLF8 mediated
cancer progression. This finding is important in addition to already identified role of
KLF8 in cancer which has been studied mostly in vitro and in xenograft model. To
investigate KLF8 mediated tumorigenesis in a better physiologically relevant system, we
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established the first KLF8 transgenic mouse model incorporated with Cre-loxP
recombination in our second parallel study. As KLF8 has been found to be upregulated
in multiple cancers, we first overexpressed KLF8 globally. While we found spontaneous
mammary and testicular tumor in couple of these mice, strikingly almost 100% KLF8
global transgenic mice died much earlier with significantly enlarged heart compared to
their

littermate

controls.

We

further

characterized

this

disease

as

dilated

cardiomyopathy by ultrasound echocardiograph. In depth study later on discovered
KLF8 promoted systolic dysfunction leading to fatal dilated cardiomyopathy.
Interestingly, cardiomyocyte specific KLF8 transgenic mice demonstrated these similar
phenotypes further proposing an unknown function of KLF8 in cardiomyocytes.
Cardiovascular disease PCR array subsequently identified possible KLF8 regulated
gene targets including likes of STAT1, S100a8, and ATP2a2 as the cause of dilated
cardiomyopathy in this mouse model. Overall, this study discovered a novel unknown
role of KLF8 in dilated cardiomyopathy, one of the leading causes of death and further
insight into the underlying mechanism will identify KLF8 as a strong therapeutic target in
dilated cardiomyopathy alongside cancer.
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CHAPTER 1: BACKGROUND
Krüppel-like factor 8 (KLF8)

Introduction

Kruppel like factor is a widely researched transcription regulator family critical in diverse
diseases primarily in cancer [1, 2]. This family contains 17 members which share three
highly conserved Cys2His2 zinc finger motifs as CACC GT box or GC-rich element DNA
binding domain at their C-terminus. KLF family members have divergent role on their
gene targets, whereas some of them act as only activator or repressors and others act
as both. The first KLF protein KLF1 was identified as a mammalian homologue of
Drosophila gene Kruppel which followed by discovery of newer members of this family.
After its discovery, KLF8 was found to be widely expressed in different species. The
locus of KLF8 was situated on X chromosome in human [3]. KLF8 protein was found to
be expressed minimally in different tissues with the highest expression in kidney. In
contrast, KLF8 expression was observed to be increased significantly in cancer tissues
compared to normal tissues, which led to an array of research to investigate the
unknown role of this protein in oncogenesis. Currently we have a better understanding
of KLF8 structure, regulation and function in different cancers primarily breast and
ovarian cancers. Till date, KLF8 has been identified to promote cancer progression[4],
Epithelial to mesenchymal transition (EMT)[5], Metastasis [6] as a dual transcription
factor with both activator and repressor role in regulating a host of critical genes like
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CyclinD1[7], EPSTI[8], MMP9[4], MMP14[9], EGFR[10],CXCR4, E-Cadherin[5]. Overall,
KLF8 has been established as an important EMT transcription factor promoting
oncogenesis with an insight into the structure, post-translational modification, regulation
and function. Current and future studies will lead to discovering unknown potential
function and characteristics of this novel protein.
Structure of KLF8

Human KLF8 consists of 359 amino acid residues. As a transcription factor, it contains
four critical domains including an N terminal repressor domain, a transcriptional
activator domain, nuclear localization domain and C terminal DNA binding domain.
KLF8 was first discovered as a transcriptional repressor of beta-globin[11].

The N

terminal 86-90 position containing a five amino acid residue motif Proline-ValineAspartic acid-Leucine-Serine (PVDLS) was identified as the repression domain of
KLF8[12]. KLF8 transcriptional repressor activity was found to depend on interaction of
this PVDLS domain with C-terminal binding protein (CtBP), a transcriptional corepressor protein. KLF8 shares this domain with some of the other KLF members like
KLF3, KLF12 [13]. Except beta-globin and E-Cadherin, KLF8 activates most of its gene
targets suggesting transcriptional activator as the predominant role of KLF8. In depth
research has revealed that the glutamine residues Q118 and Q248 of KLF8 are critical
for its transcriptional activator function as abolishing these sites hinder KLF8 mediated
activation of its targets[14]. KLF8 nuclear localization is absolutely essential as its
function which led to identifying Serine 165 and Lysine 171 as critical sites for KLF8
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localization to nucleus[15]. While the exact role of these two sites on KLF8 nuclear
localization remained mysterious, it was speculated that PKC phosphorylation on KLF8
S165 facilitates importin-beta binding through these sites leading to translocation of
KLF8 to the nucleus, as both these site specific mutants and PKC inhibitor treatment
prohibited KLF8 from localizing into nucleus, thereby inhibiting KLF8 mediated
regulation of its downstream targets. Finally the three Zn finger motifs on C terminal of
KLF8 triggers KLF8 binding to its target gene promoters. These DNA binding motif of
KLF8 is conserved between different KLF family members. Truncation mutant of KLF8
without this motif inhibits KLF8 mediated downstream gene regulation by abolishing its
binding to target gene promoters. The Zn finger domains of KLF8 also found to mediate
KLF8 interaction with other protein. PARP1 was discovered to interact with KLF8
through this C terminal motif [16, 17]. In absence of this Zn finger domain, KLF8 and
PARP1 interaction is diminished. PARP1 interaction to KLF8 was proved essential for
KLF8 nuclear localization as it prevents KLF8 binding to nuclear exporting protein
CRM1. In PARP1 null cells, KLF8 was mostly found to be localized in cytoplasm and
had a very short half-life as in absence of this interaction; KLF8 is exported to cytoplasm
by CRM1 and presumably degraded by proteasome complex affecting overall KLF8
function. PARP1/KLF8 interaction further recruits KLF8 to the DNA damage site which
led to discovery of a novel function of KLF8 in DNA repair [1, 16, 18].
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Post-Translational Modifications of KLF8

Post translational modification of a protein is critical for its physiological expression and
functions. Most of the KLF members undergo diverse post-translational modifications
regulating their function in both positive and negative manners [1]. Our protein of
interest is no exception of it. Till date, KLF8 has been identified to be regulated by
various post-translational modifications including sumoylation[19], acetylation[14],
ubiquitination, parylation[17] and phosphorylation. KLF8 was first found to be
sumoylated at Lysine 67 residue by Sumo-1, Sumo-2 and Sumo-3; primarily Sumo-1.
KLF8 interacted with the PIAS family of SUMO E3 ligases PIAS1, PIASy, and PIASxα
which triggers KLF8 sumoylation[19]. CtBP binding to the PVDLS domain recruits E2
and E3 ligases to KLF8 to enhance KLF8 sumoylation. Sumoylation of KLF8 delimits
KLF8 transcriptional activity as desumoylation increased both KLF8 mediated
transcriptional activation and repression[20]. In contrast, sumoylation of KLF8 was
critical for PARP1 mediated KLF8 recruitment to DNA repair sites. Overall this limiting
role of KLF8 sumoylation suggested that in normal physiological condition, KLF8 is
sumoylated when it is not required but it goes through desumoylation to regulate
downstream targets when needed. Further research also identified that KLF8 gets
acetylated at Lysine93, Lysine95 and Lysine67 by histone acetyltransferase P300 and
PCAF co-activators [14]. Interestingly as K67 was mediated by both sumoylation and
acetylation, an intra-regulatory role of these two post transcriptional modifications on
KLF8 was discovered. KLF8 acetylation at K93 and K95 inhibits sumoylation of KLF8 by
inhibiting CtBP binding to the PVDLS repression domain which revealed the reason
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behind enhance in KLF8 mediated gene expression during acetylation. Further studies
unveiled that a perfect balance between sumoylation and acetylation of KLF8 is
necessary for its function as acetylation promotes KLF8 transcriptional regulator
function whereas sumoylation limits the uncontrolled gene regulation by this protein[20].
This is extremely critical in context of cancer where KLF8 activates various gene targets
to enhance cancer progression and metastasis. KLF8 has been identified to go through
parylation mediated by PARP1 interaction [17]. Parylation of KLF8 facilitates its nuclear
localization by inhibiting CRM1 binding. In absence of parylation, KLF8 was localized in
cytoplasm with a high ubiquitination state. Current research is undergoing in order to
identify specific ubiquitination site of KLF8. KLF8 phosphorylation has not been studied
in that proportions like the other post-translational modifications mentioned. KLF8 S165
was speculated to be phosphorylated by PKC to mediate its nuclear localization [15].
KLF8 recruitment to the DNA damage site was predicted to somehow depend on KLF8
Serine 80 phosphorylation by PKC. One part of our current study addresses and
discovers a novel phosphorylation site of KLF8 critical for its protein stability and
function.

KLF8 signaling link to Cancer

Since its discovery, KLF8 has been established as a critical transcription factor in
cancer as it regulates an array of important genes like CyclinD1[7],MMP9[4], MMP14[9],
E-Cadherin[5], KLF4[11], EPSTI1[8], EGFR[10] and CXCR4, thereby playing essential
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roles in diverse cellular processes including cell proliferation, oncogenic transformation,
EMT, invasion, migration and metastasis. KLF8 was found to be upregulated in different
types of human cancers including breast, ovarian, pancreatic, liver, brain, gastric and
renal cancers. Previous research have shed light on KLF8 regulation by upstream
genes in the cancer tissues and furthermore downstream targets regulated by KLF8 for
a better understanding of the functional link of KLF8 in cancer. KLF8 acts as a
downstream effector of FAK, which promotes cell proliferation, migration mediated by
integrin signaling [7, 21]. Further studies in ovarian cancer cells demonstrated that FAKPI3K/AKT axis activates SP1 transcription factor which binds directly to KLF8 gene
promoter in upregulating its expression [21]. An inter-regulatory signaling loop was
identified among KLF8, KLF3 and KLF1, while KLF1 directly activates KLF8 and KLF3
represses KLF8 expression [13]. A recent study identified KLF8 upregulation by Wnt in
liver cancer cells [22]. Overall understanding the factors behind KLF8 upregulation in
cancers led the research towards finding downstream effectors of KLF8 to investigate
the KLF8 mediated signaling axis in cancer. The FAK/KLF8 signaling cascade identified
CyclinD1 as a direct target of KLF8. KLF8 upregulates CyclinD1 by binding directly to
GT box of its promoter and enhance cell cycle progression in ovarian cancer cells
leading to tumorigenesis [7]. KLF8 regulation of CyclinD1 was found to play a partial
role in KLF8 mediated oncogenic transformation of NIH3T3 cells. Ectopic expression of
KLF8 induced transforming phenotype in these cells including serum independent
growth, loss of contact inhibition between cells and change in cell morphology[23].
Inhibition of KLF8 also reduced Src mediated oncogenic transformation which
establishes a synergistic role of both these FAK downstream proteins in promoting
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cancer. KLF8 could also induce tumorigenesis as it represses tumor suppressor KLF4
by binding to its promoter. KLF8 was found to promote EMT by transcriptionally repress
epithelial cells marker E-cadherin [5]. EMT is a critical step which facilitates benign
cancer epithelial cell to divide and migrate on their own to become more malignant
cancer cells and thereby enhances metastasis and cancer related death. Along with
Snail, Twist, Zeb; KLF8 also has been established as an independent EMT inducing
transcription factor[24]. KLF8 downregulates E-cadherin in transforming epithelial cells
to more fibroblast like mesenchymal cells and enhance their survival in circulation by
inhibiting anoikis-cell detachment from extracellular matrix mediated apoptosis
method[5]. KLF8 also upregulates MMP9 and MMP14 directly in promoting breast
cancer cell invasion, migration and overall metastasis as MMPs facilitates breakage of
extracellular matrix[4, 9]. KLF8 knockdown in lung metastatic breast cancer cells
inhibited breast tumor formation and lung metastasis in xenograft and tail vein nude
mouse models and were rescued by overexpressing the downstream gene targets.
KLF8 activates a novel protein EPSTI1 in order to promote breast cancer invasion and
metastasis [8]. KLF8 role as dual transcription factor was evident in an interesting study
identifying that KLF8 mediates breast cancer malignancy through EGFR by
transcriptionally activating it directly and transcriptionally repressing miR141, an
inhibitory microRNA of EGFR in a KLF8/EGFR/miR141 axis[10]. A recent study
identified G protein coupled receptor CXCR4 as a direct target of KLF8. Novel role of
KLF8 in transendothelial migration was discovered by this study as CXCR4 upregulation
by KLF8 promoted transendo-migration and overall metastasis in breast cancer cells. A
novel link between KLF8 and cancer stem cells has been established by a current study
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which demonstrated that KLF8 induces tumorigenic mammary stem cells by
upregulating miR146a[25]. Although KLF8 has been studied primarily in breast and
ovarian cancers, various new studies are exploring its role in other cancers like renal,
gastric, liver and brain cancers as KLF8 was first identified to have elevated expression
level in all these cancer types. Silencing KLF8 in renal carcinoma cells induced
apoptosis and inhibited cancer cell invasion in vitro and xenograft models [26]. KLF8
knockdown in gastric cancer cells showed less tumorigenesis in xenograft model by
inhibiting KLF8 mediated upregulation of CyclinD1, BCL-2 and downregulation of P27
and Bax[27, 28]. Lentivirus base KLF8 knockdown also demonstrated reduced SGC7901 gastric cancer cell proliferation and invasion [29, 30]. Another study in gastric
cancer cells identified TGF-beta as the upstream activator of KLF8/E-Cadherin link in
promoting EMT in these cells [31]. A comprehensive study with 154 human gastric
cancer patients revealed that high expression of KLF8 is significantly correlated with
gastric cancer progression and poor prognosis suggesting KLF8 can be used as a
therapeutic target or biomarker for this disease[32]. In human hepatocellular carcinomas
(HCC), the aberrant overexpression of KLF8 was correlated with the metastatic
potential, post-surgical recurrence of the HCC tumors and poor survival studied in more
than 300 patient cases[33]. KLF8 promotes proliferation and invasion and inhibits
apoptosis through upregulation of cyclin D1, MMP2, BCLxL, E to N –Cadherin switch
and transcriptional repression of caspases 3 and 9 in these cells. Current studies have
suggested a novel role of KLF8 in mediating Wnt to β-catenin signaling to activate the
transcription of c-Myc, cyclin D1 and Axin1 in enhancing HCC cell proliferation [22]. An
early study in U-251MG human glioblastoma cells demonstrated evident dependence of
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KLF8 expression on FAK activity and correlation with the increase/decrease of cyclin
D1/p27 in the context of cell cycle progression[34]. Subsequently, a recent study
showed that these glioblastoma cells can go through apoptosis by silencing KLF8 [34,
35].

A novel interaction between KLF8 and androgen receptor has been recently

discovered to be critical for prostate cancer cell proliferation [36].

KLF8 role in

colorectal cancer has been demonstrated by KLF8 mediated direct activation of FHL2
which results in induction of EMT and metastasis of this cancer [6]. Inhibiting MEK/ERK
pathway reduced KLF8 and tumorigenesis in colorectal cancer cells [37]. MiR-135a was
identified as an inhibitory micro RNA of KLF8 which decreases lung cancer progression
by downregulating KLF8 expression [38]. KLF8 was also found to be critical for bladder
cancer proliferation and migration[39]. In addition, one study showed that KLF8 is an
important regulator of oral cancer cell as knockdown of KLF8 in CAL27 oral cancer cells
inhibits proliferation of these cells [40]. In another study with human pancreatic cancer
tissue, KLF8 high expression was observed to correlate with poor prognosis of the
disease[41]. Growing importance of KLF8 in different types of cancer was further
evident from couple of recent studies about KLF8 inhibition leading to decrease in cell
proliferation and invasion potential of Saos-2 osteosarcoma cells[42] and SUNE1-5-8F
nasopharyngeal carcinoma cells[43] both in vitro and xenograft models. Overall KLF8
has been observed to have critical role in oncogenesis in various cancer types and
ongoing studies will provide better understanding of any other unknown function of
KLF8 in cancer in establishing KLF8 as a possible therapeutic target in cancer
treatments.
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KLF8 in other diseases

Although primary functions of KLF8 have been primarily explored in cancer till date, few
studies suggest a widespread scope of KLF8 involvement in other diseases. A novel
developmental role of KLF8 was established by a study where they observed KLF8 to
be downregulated during preeclampsia, which is a pregnancy disorder [44]. KLF8 was
found to be expressed in the trophoblast layer, the outer layer of blastocyst in the first
trimester.

This

study

demonstrated

that

hypoxia-reoxygenation

downregulates

KLF8/MMP9 signaling axis inhibiting trophoblast invasion which reveals that KLF8 can
act as a novel oxygen tension sensor in pathogenesis of preeclampsia[45]. Further
studies are required to get insight of the mechanistic approach. Recently KLF8
expression in brain has been characterized. In zebrafish model, it has been
demonstrated that KLF8 regulates P53 and met expression to maintain neuronal
progenitor cells which is critical for zebrafish cerebellar development[46]. KLF8 was
found to be down regulated in advanced stages of Alzheimer’s disease. In depth study
identified KLF8 mediated activation of Wnt-beta catenin signaling inhibited NF-kB
signaling as beta-catenin prevents NF-kB to translocate to nucleus. This KLF8 mediated
indirect downregulation of NF-kB leads to decrease in amyloid precursor protein (APP)
and Tau expression and overall decrease in Taupathy in Alzheimer’s disease. Overall
this study established a novel inhibitory role on Alzheimer’s disease progression [47]. A
novel signaling link was discovered in adipogenesis where KLF8 was demonstrated to
transcriptionally activate peroxisome proliferator-activated receptor γ (PPARγ) and
CCAAT/enhancer-binding protein α (C/EBPα) directly in order to promote adipocyte
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differentiation[48]. Taken together, involvement of KLF8 in diverse diseases beside
cancer is being studied in order to evaluate significance of this novel protein in a myriad
of physiological disorder [48].

Figure

Figure 1. Schematic structure of KLF8 protein and its post-translational
modifications [2]
KLF8 interacts with the transcriptional co-repressor C-terminal binding protein (CtBP) through its
repression domain (RD or PVDLS motif), with the transcriptional co-activators P300 and PCAF
histone acetyl-transferases through its activation domain (AD centered on Q118/Q248), with
target DNA GT-box sequence via the three C2H2 zinc-finger (ZnF) motifs. KLF8 also binds to
importin through its nuclear localization signal sequences and PARP-1 at the ZnF region to
regulate its nuclear localization. The acetylation sites and sumoylation site of KLF8 are also
shown.
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Genetically Engineered Mouse Models

Introduction

Genetically engineered mouse model is an important tool in in vivo research [49-51]. In
1974, Rudolf Jaenisch first invented genetic modified mouse by inserting a DNA virus
into early embryo [52, 53]. Since then, the research area of genetically modified mice
has been advanced impressively in establishing new methods of incorporating
transgene into mice and knocking out critical genes from mouse genome[54-57]. Mouse
organs and tissues mostly mimic human tissues and with these engineered mice, there
has been a significant improvement in assessing critical role of various genes in diverse
diseases in a best physiological condition[58]. Compared to xenograft nude mouse
models, these engineered mice have intact immune systems to provide physiological
relevance to the human context [59, 60]. Additionally, mice can be housed in a large
number and a litter of mice have a large number of homogenous mice to provide proper
controls to study [61, 62]. Genetically engineered mice can be of different types,
primarily transgenic and knock out mice. In transgenic mice the human gene of interest
is incorporated into mouse genome under a strong promoter to study its role in relevant
diseases[63]. In contrast, a knock out model replaces the functional gene of interest
with a non-functional gene mutant by homologous recombination to investigate the
function of that particular gene. A relevant example is a transgenic mouse model for an
oncogene and a knockout mouse model for a tumor suppressor gene where both of
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them will be studied to explore tumorigenesis. The discovery of the Cre-loxP and FLPFRT based recombination has advance field further by providing an ideal platform for
tissue specific gene overexpression and knockout. This techniques in contrast to
primitive models, helps us to study effect of our gene of interest in specifically the target
tissue [64-68]. Advance techniques also include gene expression under tamoxifen
induced promoter, which developed a system where providing tamoxifen through mouse
drinking water can turn on the gene expression and it depletes out in absence of this
drug[69]. Overall the genetically engineered mouse models provide a mammalian
system to test our in vitro, xenograft model derived hypothesis in vivo. It has been found
by different studies that micro environment is critical for different diseases. In context of
cancer, tumorigenesis and angiogenesis depends greatly on interaction with the
surrounding stroma and immune cells [70, 71]. Compared to a heterogeneous human
population, where various adaptive factors like genetic background, environmental
effect, and lifestyle can regulate progression of a disease, in a much simple
homogenous mouse model, these variable conditions can be kept constant to study the
specific function of a gene of interest in that disease progression. Finally, the genetically
engineered mouse models for diverse diseases provide a more physiologically relevant
in vivo tool to study efficacy of therapeutic drugs before pre-clinical trials in humans.
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Establishing KLF8 transgenic mouse model

KLF8, an important transcription factor has been found to promote cancer progression
and metastasis[2]. All of these studies have been performed in cell culture and
xenograft nude mouse models. To investigate role of KLF8 in oncogenesis in a more
physiologically relevant system, we started constructing the first novel KLF8 transgenic
mouse model for spontaneous tumorigenesis study. Other transgenic mouse models
for mostly studied oncogenes like Myc, Ras, Her2 has developed spontaneous
mammary, lung tumor formation and it was observed that these transgenic mouse
models mimic human cancers[72-77]. As there are no studies till date exploring role of
KLF8 in a KLF8 transgenic model, in the other part of our study we started establishing
this novel transgenic model. To construct any transgenic model, we require a transgene
cassette with the gene of interest. As a mammalian expression promoter, we utilized a
synthetic promoter named CAG where C stands for cytomegalovirus early enhancement
element (CMV)[78-80], A stands for the promoter followed by the first exon and intron of
chicken beta actin gene and G stands for the splice acceptor of the rabbit beta-globin
gene. As KLF8 was primarily studied in breast and ovarian cancers, we decided to
establish a transgenic model equipped with Cre-LoxP system to explore role of KLF8
independently in different tissues. The overall scheme of KLF8 transgenic mouse
construction is described in details in the methods section of Chapter 3. Briefly the
transgene plasmid contained a HA tagged human KLF8 cDNA followed by A GFPLuciferase fused cDNA (GL) under CAG promoter. A RFP gene with STOP codon
flanked by the loxP sites was inserted upstream of KLF8 sequence. The STOP codon
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prevented KLF8 expression in the founder mice while only Cre recombination can
release the RFP-STOP cassette and induce HA tagged KLF8 expression followed by
GL. As KLF8 has been found to have critical role in different cancers, we first
constructed global KLF8 transgenic mice with aberrant overexpression of KLF8 in all
tissues to explore spontaneous tumorigenesis, although our primary aim was to induce
KLF8 expression in mammary tissue by recombination with mammary specific Cre
mice. Interestingly, the KLF8 global transgenic mice, both male and female started
dying much earlier compared to the littermate controls without any trace of
tumorigenesis. While investigating further by necropsy of these mice, we found an
exciting novel cardiac phenotype promoted by KLF8 in these mice. KLF8 global
transgenic mice were observed to have severe dilation of heart which caused the higher
mortality rate in them. A string of in depth studies described in chapter 3 revealed an
unknown novel role of KLF8 in cardiomyopathy, further establishing the importance of
genetically engineered mouse models in discovering unknown potential of individual
genes in a better physiological context.

Advantage of our mouse model

The primary advantage of our genetically engineered KLF8 transgenic mouse model is
incorporating the transgene with a Cre-LoxP system. Both Cre recombinase and loxP
sequence were first isolated from bacteriophage P1 and implied in engineered mouse
models. Cre recombinase identifies and binds to the LoxP sequences to form a dimer

15

[67, 81-83]. In this system, a transgene is inserted with two loxP sites. The position of
the loxP sites on the transgene depends on the expected gene expression. In
transgenic mouse models, generally a reporter protein followed by a STOP codon is
inserted in between two loxP sites, upstream of the gene of interest whereas in
knockout model, the gene of interest designed between the loxP sites. The mechanism
behind Cre-LoxP based recombination relies on Cre recombinase binding to both loxP
sites forming a tetramer and excising the DNA flanked by loxP sites. In case of
transgenic models, Cre recombination will excise the STOP codon flanked by LoxP in
order to promote expression of gene of interest, whereas in KO model, the gene of
interest will be excised as it is flanked by loxP sites to delete it from the genome. The
best use of Cre-LoxP based method is inducing tissue specific expression. The founder
mice with loxP flanked transgene in their genome are known as floxed mice. Cre mice
are designed with Cre transgene under various tissue specific promoters. Myh6-Cre [84]
mouse facilitates Cre expression specifically in cardiomyocytes as the Cre transgene is
placed under a Myh6 promoter which is expressed predominantly in cardiomyocytes.
The founder floxed mice can be crossed with diverse tissue specific Cre mice to induce
transgene overexpression or knock out by promoting Cre mediated recombination in
those tissues. In our transgenic mouse model, floxed KLF8 can be crossed with any
different tissue specific Cre mice to excise the loxP flanked RFP-STOP cassette and
facilitating KLF8 overexpression in that specific tissue. We used EIIA-Cre [85] mice to
develop global KLF8 transgenic mice, as EIIA promoter expresses Cre in germline
distributing it in all different tissues. Later on we also used Myh6-Cre [84] to construct
cardiomyocyte specific KLF8 transgenic mice, Adipoq-Cre[86] to construct adipocyte
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specific KLF8 transgenic mice and MMTV-Cre[87] to construct mammary epithelial cell
specific KLF8 transgenic mice. This system in our founder floxed mice provides a huge
platform to study role of KLF8 in any different tissues, thereby establishing a great
potential of this KLF8 genetically engineered mouse model in exploring role of KLF8
beyond cancer and other diseases. The advantage of the reporter genes is to visualize
the Cre base d recombination and transgene expression both qualitatively and
quantitatively. As our transgene contains a loxP flanked RFP gene and GFP-Luciferase
downstream of KLF8, Cre recombination mediated KLF8 overexpression can be
evaluated by an evident RFP to GFP-Luciferase switch which was visualized in vitro by
fluorescence imaging, luminescence an in vivo by Bio Luminescence Imaging and Bio
Fluorescence imaging. This system provides a great tool for investigating efficacy of the
Cre-loxP system of the transgene, tissue specific transgene expression and further
genotyping the transgenic mice. Taken together, we have established the first KLF8
transgenic mouse model which will have a significant impact on research of KLF8 and
beyond.
KLF8 knockout mouse model

To assess the critical role of KLF8 in vivo, we also started constructing a KLF8 knock
out mouse model. The KLF8 KO mouse model, also equipped with Cre-LoxP based
system is being maintained by Dr. Heng Lu in our lab. The Floxed KO mouse has been
constructed by replacing endogenous mouse KLF8 gene with LoxP flanked KLF8 gene
by homologous recombination. Cre recombination will delete the KLF8 gene by excising
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it between the loxP sites to provide KLF8 KO model in different tissues. We are
currently studying KLF8-KO mouse model in different tissues like global, cardiomyocyte,
and adipocyte. Both global and cardiomyocyte specific KLF8 KO mice had the reverse
cardiac phenotype, observed in transgenic mice which thereby strengthen our
hypothesis regarding the novel role of KLF8 in cardiomyopathy. Global KLF8 KO mice
further showed increased abdominal fat mass which suggests a notion about KLF8
involvement in adipocyte differentiation. Ongoing studies will provide a better
understanding about it. Thus, we currently have both KLF8 transgenic and KO models
with different tissue specific distribution potential, presenting us a critical tool for
addressing the unexplored roles of KLF8 in vivo.

Cardiomyopathy

Introduction

Cardiomyopathy in simple definition is cardiac muscle disease. It describes a large
spectrum of diseases related to heart muscle. Cardiomyopathy is the leading cause of
death[88]. According to Framingham heart study, 1 out of 5 of us has high risk of having
heart disease during our life span [89-91]. American Heart Association defined
cardiomyopathy as “Cardiomyopathies are a heterogeneous group of diseases of the
myocardium associated with mechanical and/or electrical dysfunction that usually (but
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not invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a
variety of causes that frequently are genetic. Cardiomyopathies either is confined to the
heart or is part of generalized systemic disorders, which may lead to cardiovascular
death or progressive heart failure-related disability” [92]. A broad array of factors has
been elucidated to be critical for different cardiomyopathies which made classification
and prognosis of a specific cardiomyopathy much more critical. American Heart
Association divided cardiomyopathy into two broad groups which further have different
subgroups [93, 94]. Primary cardiomyopathy affects the heart alone and secondary
cardiomyopathy affects the heart due to disease in other tissues systemically. Incidence
of the primary cardiomyopathy is much more prevalent and causes progressive or
sudden cardiac arrest[95]. Further this primary cardiomyopathy is classified into four
groups;

dilated

cardiomyopathy

(DCM),

Hypertrophic

cardiomyopathy

(HCM),

Restrictive cardiomyopathy and Arrhythmogenic Right Ventricular cardiomyopathy
(ARVC) based on pathophysiology and characteristics. All these four groups can be
further subtyped into several groups based on the underlying cause of the disease.
Disease to primary characteristic phenotype illustrates dilated cardiomyopathy with
enlarged heart, hypertrophic cardiomyopathy with thickening of heart muscle, restrictive
cardiomyopathy with

stiff

heart muscle

and

arrhythmogenic

right

ventricular

cardiomyopathy with abnormal electrical force transmission[96]. Overall this section of
the background will elaborate on these four types of cardiomyopathy with most
emphasis on dilated cardiomyopathy including its causes and treatments.
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Dilated Cardiomyopathy (DCM)
Introduction
Dilated cardiomyopathy is defined by enlargement of heart with systolic dysfunction.
This type of cardiomyopathy initiates from stretching of heart muscle leading to the
dilation of left ventricle [97, 98]. Dilated cardiomyopathy occurs primarily between 30 to
60 years of age with more prevalence in men[97]. Patients diagnosed with this disease
show distinct systolic dysfunction. Systolic dysfunction is characterized by decreased
contractile efficiency of cardiac muscle[99]. Overall this disease results in increased
myocardial mass and volume. Ischemic cardiomyopathy which is defined as the heart
disease caused by coronary artery disease primarily artery blockage, culminates into
similar phenotype as dilated cardiomyopathy which makes the diagnosis of this disease
critical [100]. Dilated cardiomyopathy is an irreversible disease of cardiac muscle cells
whereas ischemic cardiomyopathy occurs due to lack of blood flow and oxygen influx
due to artery blockage and can be reversed by treating the coronary artery disease.
Dilated cardiomyopathy is a progressive disorder as the dilation of left ventricle due to
stretching of cardiac muscle, further enhances dilation of right ventricle and overall heart
which leads to deterioration of cardiac function and severe heart failure[92]. The primary
symptoms associated with this disease are shortness of breath and fatigue. Taken
together, dilated cardiomyopathy is a non-ischemic cardiomyopathy with systolic
dysfunction. Decreased pumping efficacy of the left ventricle further causes fluid
accumulation in lung, which is known as cardiogenic pulmonary edema.
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Characteristic
The most predominant characteristic of dilated cardiomyopathy is impaired systolic
function[101]. Echocardiography is one of the critical measures to diagnose this
disease.

Echocardiograph

of

patients

suffering

from

dilated

cardiomyopathy

demonstrates increase in left ventricle end systolic and diastolic diameter. Further
decrease in ejection fraction and fractional shortening indicate the onset of this disease
[102-104]. In human, ejection fraction less than 45% and fractional shortening less than
25% generally diagnose dilated cardiomyopathy[105]. Based on underlying cause,
dilated cardiomyopathy can be sub grouped into three types including familial dilated
cardiomyopathy (FDCM), idiopathic dilated cardiomyopathy (iDCM) and other dilated
cardiomyopathy. Genetically inherited forms of dilated cardiomyopathy are known as
familial DCM which contributes to 30% of this disease occurrence [106-108]. Idiopathic
dilated cardiomyopathy is defined as DCM with unknown underlying cause[109]. Other
dilated

cardiomyopathy

cardiomyopathy,

alcoholic

includes

peripartum

cardiomyopathy[111],

cardiomyopathy[110],
toxic

valvular

cardiomyopathy[112]

and

tachycardia induced cardiomyopathy[113]. Hearts of patients diagnosed with this
disease show prominent myocardial fibrosis [114, 115]. Cardiomyocyte cells are
observed to be elongated with the nucleus spread along their width [116]. Decreased
contractile efficiency in these cardiomyocytes links to the systolic dysfunction
characteristic of this disease. In addition, large number of these cardiomyocytes goes
through apoptosis and gets replaced by fibrous tissue leading to myocardial fibrosis.
Overall dilated cardiomyopathy is a progressive heart failure associated with systolic
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dysfunction which promotes ventricle chamber enlargement further leading to
irreversible myocardial infarction.
Pathophysiology
The underlying mechanism of dilated cardiomyopathy is not clearly understood which
defines most of its occurrences as idiopathic cardiomyopathy. Familial cardiomyopathy
which is involved in approximately thirty percent of this disease is genetically inherited
[108, 117-120]. The cause of genetic dilated cardiomyopathy is being explored and till
date several critical gene mutations have been identified in patient’s heart with this
disease[118]. Most of these mutants are inherited in an autosomal dominant pattern and
leads to dilated cardiomyopathy. Family history is one of the critical factors of diagnosis
of this disease due to increased understanding of the genetic complexity. Sarcomere is
the basic unit of striated muscle cells consisting of two major proteins myosin and actin,
the first forming the thick filaments and later forming the thin filaments of the muscle
fibers. Actin binding to the globular head of myosin mediates myocardial contraction.
Stimulation by axon potential promotes a calcium induced calcium release from the
sarcoplasmic reticulum of cardiac muscle cells. Calcium ions bind to the tropomyosin
(cardiac troponin) and change its structural conformation to expose the actin binding
sites on myosin, leading to contraction of these cells. Most of the sarcomere genes
have been identified to be mutated in dilated cardiomyopathy and contractile
dysfunction [121-125]. These mutants were also characterized as dominant negative
mutants of these sarcomere genes affecting both the force generation and force
transmission in context of cardiomyocyte contraction. Genes associated with dilated
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cardiomyopathy includes Cardiac actin[126], Desmin[127], δ-Sarcoglycan[128], βMyosin

heavy

chain[129],

Cardiac

troponin

T[130],

α-Tropomyosin[131],

Metavinculin[132], Myosin-binding protein C[133], Muscle LIM protein[134], α-Actinin2[134],

α-Myosin

heavy

chain[135],

SUR2A[136],

Lamin

A/C[137],

Phospholamban[138], Cypher[139] etc. Mouse models with these gene mutants knock
in demonstrated severe dilated cardiomyopathy. Dominant negative mutation in βMyosin heavy chain and Cardiac troponin T diminishes actin myosin binding further
decreasing force generation and contractile potential of muscle cells. Additionally
ablation of structural proteins like α-Actinin-2, δ-Sarcoglycan inhibits actin binding to the
extracellular matrix, thereby sacrificing the transmission of contractile force between
cardiomyocytes. Mutation in phospholamban, a sarcoplasmic reticulum calcium
regulator further abolishes calcium induced calcium release and contraction [138]. All of
these sarcomere, Z disc and cytoskeleton associated genes regulate cardiomyocyte
contraction. Familial mutation in these proteins overall ablates cardiomyocyte
contraction efficacy leading to lower ejection fraction and fractional shortening. In order
to increase its systolic function, heart undergoes a remodeling process and tends to
increase its size to accumulate more amount of blood in the left ventricle, thereby
leading to dilated cardiomyopathy. One of the other primary causes of dilated
cardiomyopathy is myocarditis which is promoted by viral agents mediated cleavage of
a cytoskeleton protein dystrophin leading to loss of cardiomyocyte integrity [140].
Peripartum cardiomyopathy develops in the last trimester of pregnancy[110]. Valvular
cardiomyopathy develops due to increase in cardiac work load due to valve dysfunction.
Further, abnormal alcohol consumption also leads to alcoholic cardiomyopathy[50].
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Advance researches are being focused to explore the underlying genetic complexity
behind incidence of different types of dilated cardiomyopathy.
Current Treatments

Genetic counseling is the primary line of treatment to evaluate the history of dilated
cardiomyopathy. Family history of this disease suggests genetic cardiomyopathy.
Echocardiograph and MRI are used primarily to diagnose systolic dysfunction and
dilated cardiomyopathy. Once the disease has been observed to be progressed, the
early pharmacological treatments include ACE inhibitors, diuretics and beta inhibitors
which improve the ejection fraction and systolic function of heart[141]. Angiotensinconverting-enzyme inhibitor (ACE inhibitor) is a drug generally used to treat
hypertension. It helps cardiomyocyte cells survive with less oxygen in a more stressful
condition. Diuretics prevent dilated cardiomyopathy associated pulmonary edema.
Combined treatments of ACE inhibitor and diuretics delay disease progression of dilated
cardiomyopathy. Beta blockers like bisoprolol, metaprolol decreases the risk of sudden
cardiac death of patients with dilated cardiomyopathy. One study with 25 mg
spironolactone significantly diminished the risk of sudden death by 30% in human
patients with EF less than 35%, thereby further clarified the efficacy of beta
blockers[142]. After the disease has progressed to further critical stages with evident
enlargement of left ventricle, cardiac resynchronization therapy with biventricular pacing
is used to treat systolic dysfunction and worsening of the disease. Currently the only
treatment for late stage of dilated cardiomyopathy is orthotopic heart transplantation.
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Left ventricular assist device is used to maintain the heart condition during waiting time
for organ availability. In some cases, where organ transplant is not possible, left
ventricular assist device is critical for improvement of quality of life.

Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy is characterized by increase in ventricle wall thickness
without any occurrence of coronary artery disease. This is the most prevalent
cardiomyopathies with a high incidence of 1 in 500 individuals all over the word. Genetic
cause behind this disease is much better understood in comparison with dilated
cardiomyopathy [143-146]. The primary two genes which are predominantly observed to
be mutated in patients with hypertrophic cardiomyopathy are beta-myosin heavy chain
and myosin-binding protein C[147]. Various autosomal dominant mutants of these two
genes have been found to be involved in the onset of seventy percent of this disease.
Till date, almost five hundred mutations have been discovered from 13 different genes
[148]. In this disease, cardiomyocyte hypertrophy increases the cell size as more
sarcomere units are added. Overall this leads to thickening of ventricle walls, primarily
in left ventricle. Thickening of the heart walls and intraventricular septum further
mediates narrowing of the ventricle chambers. Echocardiography is the first measure to
assess the progression of this disease. Patients diagnosed with hypertrophic
cardiomyopathy demonstrate increased left ventricle posterior wall and intraventricular
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septum thickness. In some incidents, hypertrophic cardiomyopathy develops into dilated
cardiomyopathy [146, 149].

Restrictive Cardiomyopathy

Restrictive Cardiomyopathy is associated with restricted cardiac filling of heart leading
to decrease in diastolic volume and diastolic dysfunction. Prognosis of this type of
cardiomyopathy is very difficult as it doesn’t show change in ventricle or wall size as
other two types of cardiomyopathy. Patients with this disease don’t show any systolic
function abnormality. In some incidents, later stage of the disease can impair systolic
function. Restrictive cardiomyopathy can be idiopathic or associated with diseases like
amyloidosis and endomyocardial disease with hypereosinophilia. Recently in depth
studies revealed that restrictive cardiomyopathy is also associated with sarcomeric
gene mutations in some cases [150]. Discovery of genetic background of this type of
cardiomyopathy has been proven critical in proper diagnosis and prediction of restrictive
cardiomyopathy. This disease first effect the left ventricle relaxation which further
distributes to the right ventricle causing congestive heart failure [151, 152].

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Arrhythmogenic

Right

Ventricular

Cardiomyopathy

(ARVC),

also

known

as

Arrythmogenic Right Ventricle Dysplasia (ARVD) is a nonischemic heart disorder.
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Cardiomyocytes are linked together by a protein complex known as desmosome and
this interconnection between cardiomyocyte is essential in maintaining a healthy systolic
function. The primary cause behind ARVC has been established to be mutation in a
desmosome protein desmin[153]. Progression of this disease starts from apoptotic
death of myocyte and fatty tissue infiltration in myocardium of primarily right ventricle. At
this stage, this disease is still in concealed phase as it doesn’t show any defect in right
ventricle yet like thinning of right ventricle posterior wall. Further the fibro-fatty tissue
replaces right ventricular myocardium leading to thinning of wall and irregular cardiac
rhythm which can be measured by echocardiograph and EKG. Previously it was
believed that ARVC initiates in right ventricle and during later stages it spreads into left
ventricle to become biventricular cardiac disorder. Few studies elucidated recently that
the detrimental effect on left ventricle happens from the onset of the disease. Overall
symptom of this disease is abnormal heart rhythm, palpitation, shortness of breath.
Current treatment includes implantable cardioverter defibrillator (ICD) implantation
which reverses irregular cardiac rhythms by providing electrical shock to heart. In
extreme cases, patients with disease go through heart transplant surgery [154].
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CHAPTER 2: ERK2 PHOSPHORYLATES KRÜPPEL-LIKE FACTOR 8
PROTEIN AT SERINE 48 TO MAINTAIN ITS STABILITY
Am J Cancer Res. 2016 May 1;6(5):910-23

Abstract

Krüppel-like factor 8 (KLF8) plays important roles in cancer and is strictly regulated by
various post-translational modifications such as sumoylation, acetylation, ubiquitylation
and PARylation. Here we report a novel phosphorylation of KLF8 by ERK2 responsible
and critical for the stability of KLF8 protein. The full-length KLF8 protein displays a
doublet in SDS-PAGE gel. The upper band of the doublet, however, disappeared when
the N-terminal 50 amino acids were deleted. In its full-length the upper band
disappeared upon phosphatase treatment or mutation of the serine 48 (S48) to alanine
whereas the lower band was lost when the S48 was mutated to aspartic acid that
mimics phosphorylated S48. These results suggest that S48 phosphorylation is
responsible for the motility up-shift of KLF8 protein. Pharmacological and genetic
manipulations of various potential kinases identified ERK2 as the likely one that
phosphorylates KLF8 at S48. Functional studies indicated that this phosphorylation is
crucial for protecting KLF8 protein from degradation in the nucleus and promoting cell
migration. Taken together, this study identifies a novel mechanism of phosphorylation
critical for KLF8 protein stabilization and function.
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Introduction

Krüppel-like factor 8 (KLF8), a member of Krüppel-like transcription factor family, is
upregulated and plays important roles in various cancer types [2, 4, 6, 9, 21-23, 27, 37,
155]. KLF8 functions as a dual transcriptional factor and has been shown to repress or
activate a variety of cancer-related genes such as E-cadherin [5], KLF4 [19], cyclin D1
[7, 23], epidermal growth factor receptor (EGFR) [37], MMP9 and MMP14 [4, 9] and
epithelial-stromal interaction 1 [27]. In addition to regulating cancer-promoting
processes including transformation [23], epithelial to mesenchymal transition [5] and
metastasis [4, 9, 27, 37], KLF8 also plays a role for DNA repair [16], adipogenesis [48]
and Alzheimer’s disease [47]. Indeed, KLF8 is emerging as a critical factor for diverse
diseases [2].

Post-translational modification (PTM) is one of the most important protein regulatory
mechanisms. Previous studies showed that KLF8 undergoes sumoylation at lysine 67
[19], acetylation at lysine 93 and lysine 95, and potential phosphorylation at serine 165
and serine 80 [16, 19, 20]. The sumoylation, acetylation and their crosstalk play an
important role in KLF8 function [19, 20]. The serines 165 and 80 of KLF8 are critical for
its nuclear localization and function such as DNA repair [15, 16]. Interestingly, previous
study with KLF8 truncation mutants revealed that the doublet of KLF8 protein became a
single band when  50 amino acids were deleted from the N-terminus [15], suggesting
that a PTM in this deleted region is responsible for the mobility shift and doublet
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formation. However, none of the PTM sites on KLF8 described above is located within
this region. It has been mysterious how the mobility shift occurs and whether it has any
impact on the function of KLF8.

In this study, we provide strong evidence that mobility shift of KLF8 protein is due to the
phosphorylation at serine 48 by ERK2 and this phosphorylation is essential for
maintaining the stability and function of KLF8 protein in the nucleus.

Materials and methods

Antibodies and Reagents

Primary antibodies used for western blotting include mouse monoclonal to HA-probe (F7) (sc-7392) (1:3000), mouse monoclonal to β-actin (C4) (sc-47778) (1:4000), Mouse
monoclonal for c-Myc (9E10) (Sc-40) (1:2000), mouse monoclonal to pERK (E-4) (Sc7383) (1:2000) and rabbit polyclonal to ERK (c-16) (Sc-93) (1:2000) (Santa Cruz
Biotechnology, Inc., Dallas, TX, USA). Secondary antibodies were horse radish
peroxidase conjugated donkey anti-mouse (715-035-150) and donkey anti-rabbit IgG
(711-035-152) (both 1:5000. Jackson ImmunoResearch laboratories, West Grove, PA,
USA). Antibody used for co-immunoprecipitation was Anti-HA mouse monoclonal
(IP0010) Immunoprecipitation Kit (Sigma-Aldrich, St. Louis, MO, USA). MEK inhibitor
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PD98059 (513000) and U0126 (662005) as well as the inhibitor of protein synthesis
cycloheximide were from Calbiochem (San Diego, CA, USA). Glycogen synthase kinase
3 (GSK3) inhibitor SB216763 (S1075) was from Selleckbiochem (Boston, MA, USA).
cyclin-dependent kinase 5 (CDK5) inhibitor Roscovitine (557360) was from Milipore
(Billerica, MA, USA). c-Jun N-terminal kinase I (JNKI) inhibitor BI 78D3 (Cat. No. 3314)
and JNKII inhibitor AEG 3482 (Cat. No. 2651) were from Tocris (Ellisville, MO, USA). All
the inhibitors were reconstituted with DMSO. The alkaline phosphatase calf intestinal
phosphatase(CIP. M0290) were purchased from New England Biolabs (Ipswich, MA,
USA).

Plasmid construction

The mammalian expression vectors pKH3 (HA-tagged), pHAN (Myc-tagged), pKH3KLF8,

pKH3-KLF8-dN50,

pHAN-KLF8

and

pHAN-KLF8-dN50

were

previously

described [14]. KLF8 deletion and point mutants were constructed by site-directed
mutagenesis PCR [156] using the pKH3-KLF8 vector as the template. We used the
primer pKH3-F paired with mutant-R and primer mutant-F paired with pKH3-R for the
mutagenesis PCR and the pKH3-F and pKH3-R primer pair for overlapping PCR. The
mutant fragments were digested with HindIII and EcoRI to clone into pKH3 vector
between the sate sites. To construct lentiviral vectors pLVPZ-KLF8-S48A and pLVZPKLF8-S48D, we PCR-amplified the HA-KLF8-S48A and HA-KLF8-S48D fragments from
pKH3-KLF8-S48A and pKH3-KLF8-S48D plasmids. These fragments were digested
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with Pst1/Not1 and inserted into the lentiviral vector pLVPZ [9]. All the constructs were
verified by DNA sequencing. The human ERK2 cDNA was amplified using ERK2-SmaIF and ERK2-ClaI-R primers. This amplified fragment was digested with SmaI/ClaI and
cloned into pHAN vector between the same sites. The ERK2 dominant-negative (K54R
in which the ATP binding activity is disabled [157, 158]) and constitutively active (ERK2CA,

an

ERK2

double

mutant

consisting

of

R67S

that

promotes

ERK2

autophosphorylation and D321N that inhibits ERK2 phosphatase binding [158-160])
mutants were constructed by site-directed mutagenesis similarly. See Table 1 for
sequences of all the primers and oligonucleotides used.
Cell culture, cell line generation and transfection

The HEK293 [156, 161, 162] and MCF-7 [5, 23] cell lines were described previously.
These cells were maintained in DMEM with 10% fetal bovine serum (FBS) and proper
antibiotic supplements. MCF7 stable cells expressing HA-KLF8 (MCF7-K8) and its
mutant S48A (MCF7-K8-S48A) and S48D (MCF7-K8-S48D) were generated by
infecting the MCF7 cells with lentiviruses derived from the corresponding lentiviral
vectors followed by puromycin selection. Selected cells were maintained in DMEM
-/-

-/-

and matched wild-

type mouse embryonic fibroblasts (MEFs) were kind gifts from Dr. Jim Woodgett of
Lunenfeld-Tanenbaum Research Institute [163]. These cells were maintained in DMEM
plus 10% FBS. Transfections were done using Lipofectamine 2000 (Invitrogen, Grand
Island, NY, USA).
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Phosphatase treatment

After 36 - 48 h of transfection, cells were washed with ice-cold phosphate-buffered
saline, lysed with NP-40 buffer containing protease inhibitor cocktail (1 mM PMSF, 0.2
leupeptin) for 30 minutes at 4°C and centrifuged (12,000
rpm, 10 min, 4°C) to obtain the ce
-PAGE
and western blotting. Untreated lysate and lysate treated with CIP plus its inhibitor
sodium orthovanadate (20 mM) were included as controls.
Western blotting and co-immunoprecipitation (Co-IP)

These assays were done as previously described [5, 16]. Cells and antibodies used
were described above. Western blots were quantified using Image Lab 3.0 (Bio-Rad,
Hercules, CA) as previously described [16]

Protein lifespan assay

Cycloheximide (CHX) chase assay was performed essentially as previously described
[16]. The HA-KLF8 and its mutant proteins overexpressed either transiently in HEK293
cells or stably in the MCF7 cell lines described above were treated with 50 ng/ml of
CHX. In some experiment, the MEK inhibitor U0126 was included in the medium at 10
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time. Lysates were collected at different time points for western blotting.

Cell migration assays

MCF7, MCF7-K8, MCF7-K8-S48A and MCF7-K8-S48D cells were seeded in a 12-well
plate and grown to confluent state. Would closure (24 h) and Boyden Chamber (20 h)
migrations were performed and analyzed quantitatively as previously described [5].

Statistical Analysis

At least three observations per group were conducted. Data are presented as mean 
the standard deviation. Unpaired, paired or single sample Student’s t-test with the
Bonferroni correction for the multiple comparisons was applied as appropriate.
Statistical significance was determined using the alpha level of 0.05.
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Results

Mobility shift of KLF8 is due to phosphorylation among its N-terminal 50 amino acids

The full-length wild-type KLF8 protein migrates as a doublet on SDS-PAGE and deletion
of 50 or more amino acids from the N-terminus changes the doublet into a single band
[15] regardless of the epitope types attached (Figure 2A). Since the known PTMs of
KLF8 do not have evident effect on the mobility shift [14-17, 19, 20] and protein
phosphorylation most frequently causes protein mobility up-shift [164, 165], we sought
to determine if phosphorylation plays a role for the KLF8’s mobility shift observed. We
treated the cell lysates containing epitope-tagged KLF8 protein with calf intestine
phosphatase (CIP) that removes phosphate group from phosphorylated serine,
threonine or tyrosine. The result clearly showed that CIP treatment significantly
reduced, if not abolished, the upper band of the doublet irrespective of the tag types
(Figure 1B, compare middle to left lane). This is specific to the catalytic activity of CIP in
that the loss of the upper band was prevented with the CIP inhibitor sodium
orthovanadate (Na3VO4) [166] (Figure

2B, lane 3). Taken together, these results

strongly suggest that phosphorylation of a residue among the N-terminal 50 amino acids
is responsible for the mobility shift of KLF8 protein.

35

Phosphorylation of KLF8 at the serine 48 is responsible for the mobility up-shift

To determine the phosphorylation site, we first constructed small deletion mutants of
KLF8 by deleting 10 amino acids at a time from the N-terminal 50 amino acid region
(Figure 3A). Deletion of either the residues 31-40 or 41-50 resulted in a loss of the
upper band, whereas other deletions did not affect the mobility (Figure 3B). This result
suggested that the phosphorylated residue of KLF8 is somewhere between the amino
acids 30 and 50. To identify the exact amino acid(s) that is phosphorylated, we mutated
all the serine, threonine and tyrosine residues in the 31-50 region to alanine individually
to prevent phosphorylation. We found that only the S48A mutant migrated as a single
band with mobility identical to the lower band of the doublet (Figure 3C), whereas the
S48D mutant, where the serine was mutated to aspartic acid to mimic the
phosphorylated serine [167, 168], migrated as a single band with mobility identical to
the upper band of the doublet (Figure 3D). Thus, KLF8 is likely phosphorylated at S48,
which is responsible for the mobility up-shift. Phylogenic analysis showed that the S48
residue is highly conserved across the species (Figure 3E). Taken together, these
results provided strong evidence that the S48 can be phosphorylated which is
potentially of functional importance for KLF8.
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The amino acid 31-40 region plays a regulatory role for the phosphorylation of KLF8 at
S48

The loss of the upper band from the d31-40 mutant protein (Figure 3B) is not due to
failure to be phosphorylated within this deleted region in that mutation of the serine 31,
the only potential phosphorylation residue, to alanine did not alter the mobility of the
protein (Figure 3C). This result suggested that, while this region does not contain a
phosphorylation site, it might play a role in facilitating the phosphorylation at S48. We
then made two smaller deletion mutants of KLF8, i.e., d31-35 and d36-40 and found
that interestingly, the d31-35 mutant showed mostly the upper band whereas the d36-40
mutant migrated as only the lower band (Figure 4A). This result suggested that the
amino acid 31-35 and 36-40 regions might respectively regulate the phosphorylation at
S48 negatively and positively. Indeed, both phosphatase treatment and a second S48A
mutation brought the d31-35 mutant protein to the lower band position, while the S48Dd31-35 mutant protein remained in the upper band position regardless of the
phosphatase treatment (Figure 4B). We then mutated each residue to alanine in this
region individually or in combination and found that only the R33A/R35A mutant showed
a migration pattern closest to the d31-35 mutant (Figure 4C). This result suggested that
this R-X-R motif at 33-35 position might be the one that mediates the negative effect on
the phosphorylation at S48. To determine the core residue or motif among 36-40
residues, we similarly mutated each individual residue in this region to alanine.
Isoleucine residue at position 40 was also mutated to arginine given that isoleucine and
alanine share similar amino acid structure. All the single point-mutants migrated as a
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doublet similar to the wild-type KLF8. Because proline actively participates in protein
folding to maintain protein tertiary structure, we constructed a P37A/P38A mutant of
KLF8. It has been also reported that D-X-X-E motif is important for binding to metal ions
[169] and proteins such as focal adhesion kinase [170]. Hence, we made a D36A/E39A
mutant also to obstruct this motif. Interestingly, the D36A/E39A double mutant migrated
as the lower band only whereas the P37A/P38A mutation did not alter the mobility
(Figure 4D). These results suggested that the D-X-X-E motif at 36-39 positions
mediates the positive effect on the phosphorylation at S48. Taken together, the amino
acid 31-40 region appears to play an important counteracting role to balance a proper
level of phosphorylation of KLF8 at S48 through mechanisms to be determined (Figure
4E).

ERK2 phosphorylates KLF8 at S48

We then sought to determine the protein kinase responsible for the phosphorylation of
KLF8 at S48. We first attempted to predict potential kinase(s) for the S48 site using the
online

application

programs

including

NetPhosK

[171]

(http://www.cbs.dtu.dk/services/NetPhosK/), PhosphoNet (http://www.phosphonet.ca/)
and Kinasephos (http://kinasephos.mbc.nctu.edu.tw/). The GSK3, CDK5, ERK and JNK

score. Next, we treated the HEK293 cells overexpressing HA-KLF8 with specific
inhibitors of these kinases. Only the MEK1/2 inhibitor treatment showed less KLF8
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phosphorylation compared to DMSO treatment (Figure 5A). As the GSK3 inhibitor used
was for both GSK3 and GSK3, we transfected KLF8 into GSK3 knockout (GSK3-/-)
and GSK3 knockout (GSK3-/-) mouse embryonic fibroblast (MEF) cells [163]. KLF8
protein mobility remained unchanged in these knockout cells as in the wild-type MEF
cells (Figure 5B), thereby, excluding GSK3s. These results indicated that the MEK-ERK
pathway might play a role in the phosphorylation of KLF8 at S48.
To determine cancer relevance of the aforementioned results, we generated MCF7 cell
lines stably overexpressing the wild-type KLF8 (MCF7-K8) and the S48A mutant
(MCF7-K8-S48A), respectively. Treating the MCF7-K8 cells with the MEK inhibitors,
PD98059 or U0126, caused a dramatic reduction in the phosphorylation of KLF8 that is
well correlated with the decrease in the phosphorylation of ERKs (Figure 5C-5F). This
result suggested that MEK(s) or/and ERK(s) could be responsible for the
phosphorylation of KLF8 in the breast cancer cells. Since the above described computer
programs predicted ERK(s) rather than MEKs as a potential KLF8 kinase, and the
phosphorylation of ERK2 appeared to be inhibited more than ERK1 did by the MEK
inhibitors in the cells (Figure 5C-5F), we next tested the potential phosphorylation of
KLF8 by ERK2. Overexpression of ERK2 increased the phosphorylation of KLF8
whereas its kinase dead, dominant negative mutant (ERK2-K54R) decreased the
phosphorylation of KLF8 (Figure 5G). By contrast, the S48A mutant of KLF8 did not
show any phosphorylated upper band upon ERK2 overexpression (Figure 5G). These
results strongly suggested that ERK2 could phosphorylate KLF8 at S48. This notion
was further supported by the co-IP assay that detected an interaction between ERK2
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and KLF8 in the cells (Figure 5H). In addition, EGF stimulation of ERKs clearly
increased the phosphorylation of KLF8, which was blocked by the ERK2 dominant
negative mutant (Figure 4I). Furthermore, overexpression of the constitutively active
mutant (ERK2-CA) prevented inhibition of the phosphorylation of KLF8 by the MEK
inhibitor U0126 (Figure 5J). Taken together, these results identified ERK2 as the kinase
likely responsible for the phosphorylation of KLF8 at the S48 site.

Phosphorylation of KLF8 at S48 maintains the stability of KLF8 protein

The phosphorylation of KLF8 appears to correlate with the total levels of KLF8 (Figure
5A and 5J), suggesting a potential protection of KLF8 protein from degradation by the
phosphorylation at the S48 site. Indeed, both the phosphorylation-defective mutants,
KLF8-S48A and KLF8-d41-50, expressed at a significant lower level than the wild-type
KLF8 did (Figure 6A). We performed protein chase assays in transient transfected HEK
293 cells and found out that the wild-type KLF8 and the S48A mutant have the longest
and shortest life-span, respectively (Figure 6B and 6C). Unexpectedly yet interestingly,
the S48D and d31-35 mutants did not show a prolonged life over the wild-type KLF8
although the d36-40 mutant, like the S48A mutant, showed a shortened lifespan
compared to the wild-type KLF8 (Figure 6B and 6C). Taken together, these results
suggested that the phosphorylation at S48 is critical for maintaining the stability of KLF8
protein.
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Phosphorylated KLF8 acts as a mask to protect the overall stability of KLF8 protein

In the MCF7 stable cell lines, we obtained stability patterns for the wild-type KLF8 and
the S48A mutant similar to what was observed in the HEK293 cells (Figure 7A and 7B).
Surprisingly, the unphosphorylated form (lower band) of the wild-type KLF8 stayed more
stable than the phosphorylated form (upper band) (Figure 7B). These results raised an
interesting possibility that the phosphorylation of KLF8 at S48 helps maintain the overall
KLF8 protein levels by protecting the unphosphorylated form of KLF8 from degradation.
This notion was further supported by the result showing that the lower band of KLF8
was degraded faster in the cells treated with the MEK inhibitor than that in the mock
treated cells (Figure 7C and 7D). Therefore, the phosphorylated KLF8 may sacrifice
itself to protect the unphosphorylated form of it.

KLF8 requires the phosphorylation at the S48 site to promote cell migration

Lastly, we attempted to see if the phosphorylation of KLF8 at the S48 site plays a role
for any known cellular function of KLF8. We performed two independent migration
assays both of which demonstrated that the S48A, but not the S48D, mutant lost the
capacity to promote the MCF7 cell migration (Figure 8). This result suggested that the
phosphorylation of KLF8 at the S48 site by ERK2 is critical for KLF8 function.
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Discussion

This study identified the serine 48 as a novel phosphorylation site on KLF8 responsible
for its mobility shift and ERK2 as a novel kinase for the phosphorylation of KLF8 at this
site. Based on the results of the study, we propose a model of mechanism of action
(Figure 9) in which ERK2 phosphorylation of KLF8 at the serine 48 site gears the
degradation of KLF8 protein from the unphosphorylated towards phosphorylated form of
the protein to protect the stability of unphosphorylated form. The unphosphorylated form
may be the primary functional form of KLF8. In addition, the phosphorylation at the
serine 48 is critically balanced by N-terminal region of residues 31-40 where the regions
of 31-15 and 36-40 have a negative and positive effect, respectively via unknown
mechanisms.

In support of this study, it was reported that ERK2 phosphorylates c-Myc at serine 62 to
increase the stability of c-Myc protein [172], and blocking this phosphorylation by
inhibiting ERK2 leads to a marked decrease in the c-Myc protein level and tumor
malignancy [173]. In addition to KLF8, other KLF family members such as KLF5 [174],
KLF3 [175] and KLF2 [176] are also regulated by phosphorylation. Indeed, it has been
reported that ERK2 phosphorylated KLF2 protein is more sensitive to proteasomal
degradation [176], and ERK phosphorylation of KLF4 at serine 123 results in inhibition
of KLF4’s function [48]. Another recent report showed that ERK inhibitor treatment
decreased KLF8 expression and the ERK-KLF8 pathway might play a role in

42

chemoresistance of colorectal cancer cells [37]. Our results provide mechanistic
interpretation of this report. Our recent work has revealed that KLF8 upregulates EGFR
in breast cancer cells [37]. Given that EGF stimulation enhances the ERK2-dependent
phosphorylation of KLF8 (see Figure 5I), it is possible that a potential positive feedback
loop of KLF8 to EGFR to ERK to KLF8 exists.

We showed that both the constitutively phosphorylation-mimicking and
unphosphorylated mutants of KLF8 protein have a shortened lifespan compared to the
total wild-type KLF8 (Figure 6). However, the phosphorylated form (upper band) of wildtype KLF8 has a much shorter lifespan than its unphosphorylated counterpart (lower
band) (Figure 7). These seemingly paradoxical observations suggest a protective role of
the phosphorylated form for the stability of the unphosphorylated form that might be the
functional form of KLF8 in the nucleus.

How the amino acid 31-40 region regulates the phosphorylation of KLF8 at the serine
48 site remains to be determined. The R-X-R motif located in the 33-35 region has
been shown to play an essential role in protein-protein interaction [177], endoplasmic
reticulum (ER) retention of protein [178], and phosphatase binding [179]. This motif was
first identified as an ER retention motif [180, 181]. Proteins with this motif tend to show
high ER retention and less ER to Golgi transport [182, 183]. The positively charged
arginine (R) residues can interact with other negatively charged residues to regulate
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protein tertiary structure [184]. This motif is also involved in co-factor binding [182].
Interestingly, two reports suggested that F-X-X-R-X-R motif is the binding site of the
phosphatase PP1 [179, 185]. It will be interesting to test if the KLF8’s 30ASVRNR35 motif
plays a docking role for PP1 or PP1-like phosphatases. The D-X-X-E in the 36-39
region, unlike R-X-R motif, had a positive influence on the phosphorylation of KLF8. DX-X-E motif was first found on -integrin cytoplasmic tail critical for focal adhesion
kinase binding [170]. Recent studies have also demonstrated the binding of D-X-X-E
motif to the metal ion of magnesium, manganese or calcium [169, 186, 187]. Calcium
has been shown to activate ERK through adynyl cyclase [188]. Therefore, it is possible
that the

36

DPPEI40 motif might play a role in metal binding required for the

phosphorylation of KLF8 at the serine 48 site by ERK2.

Previous report showed that poly (ADP-ribose) polymerase 1 binds to KLF8 to promote
its nuclear retention and prevent nuclear export and subsequent degradation of KLF8
protein in the cytoplasm [17]. Interestingly, the KLF8 S48A mutant is localized in the
nucleus and the phosphorylation of KLF8 at serine 48 does not play any role in poly
(ADP-ribose) polymerase 1 binding (data not shown). Therefore, it is likely that the
stability of KLF8 protein is regulated in both the cytoplasm and nucleus via distinct
molecular mechanisms. Additionally, cross talks between different PTM types KLF8
have been reported. For instance, a switch between acetylation and sumoylation of
KLF8 was found to be critical for its transcriptional activity [20]. Whether or not the
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phosphorylation of KLF8 at the serine 48 site plays a role for other PTM types is another
interesting topic of future study.

Physiologically critical yet pathologically important proteins such as proto-oncogenic
and tumor suppressor proteins are tightly regulated to maintain their expression and
function within the physiological window. Loss of the regulatory balance is a major
cause of diseases. Both the S48 site of KLF8 and the function of ERK2 are well
conserved across species. PTMs such as protein phosphorylation are among the most
important protein regulatory mechanisms. These lines of evidence underscore the
pathological importance of the ERK2-dependent phosphorylation of KLF8 at the serine
48 site discovered in this study.
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Figures

Figure 2. Mobility shift of KLF8 is due to phosphorylation in its N-terminal 50
amino acid residues.
(A) The N-terminal region of 50 residues is required for maintaining the doublet of KLF8 protein
on SDS-PAGE gels. HA-KLF8, HA-KLF8-dN50, Myc-KLF8 or Myc-KLF8-dN50 was transfected
into HEK293 cells. Whole cell lysates were collected after 48 hours and processed for western
blotting with anti-HA (1:3000) or anti-Myc (1:2000) antibody with anti- -actin as loading control.
(B) Treatment with alkaline phosphatase abolished the upper band of the KLF8 doublet. HAKLF8 or Myc-KLF8 was oeverexpressed in HEK293 cells. Lysates prepared from the cells were
treated with CIP without or with its inhibitor sodium orthovanadate (Na3VO4) as described in the
Experimental Procedures and processed for western blotting as described above.
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Figure 3. Phosphorylation of KLF8 at the serine 48 (S48) is responsible for the upshift of KLF8 mobility.
(A, B) Both KLF8 31-40 and 41-50 aa regions are essential for the phosphorylation (mobility
upshift) of KLF8. Indicated small deletion mutants of KLF8 (A) were overexpessed for western
blotting (B). (C, D) The mobility up-shift of KLF8 is due to the phosphorylation at the S48. All the
potential phosphorylated residues including serine, threonine and tyrosine residues in the area
of residues 31-50 were mutated to alanine and their band patterns were analyzed by
overexpression and western blotting (C). Only the S48A mutant showed a single (lower) band.
(D) Mutation of S48 to Aspartate results in the upper band only. The phosphorylation-mimicking
mutant S48D was overexpressed for western blotting. (E) The S48 site of KLF8 is conserved
across the species. Sequence homology was analyzed using the NCBI multiple sequence
alignment.
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Figure 4. The region of residues 31 - 40 plays an essential regulatory role in the
phosphorylation of KLF8 at the S48 site.
The R-X-R motif in 31SVRNR35 of KLF8 plays an inhibitory role in the phosphorylation of KLF8 at
the S48 (A-C) whereas the D-X-X-E motif in 36DPPEI40 of KLF8 has a positive effect on it (D).
Indicated KLF8 mutants were overexpressed and lysates were prepared with or without CIP
treatment in the presence or absence of the CIP inhibitor for western blotting. (E) The
counteracting role of the R-X-R and D-X-X-E motifs was illustrated.
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Figure 5. ERK2 is the kinase responsible for the phosphorylation of KLF8 at the
S48 site.
(A) Inhibition of MEKs, but not JNKs, GSK3s or CDK5, leads to a decrease in the
phosphorylation of KLF8. HEK293 cells overexpressing KLF8 were treated with indicated
inhibitors for 4 h. Cell lysates were prepared for western blotting. (B) Knockout of GSK3s does
not affect mobility of KLF8 protein. Wild-type KLF8 (WT), its S48A mutant or vector control was
overexpressed in the indicated cells for 48 h. Cell lysates were prepared for western blotting.
(C-F) Dose- and time-dependent inhibition of phosphorylation of KLF8 by MEK inhibitors. The
MCF7-K8 cells at ~80% confluent growth were treated with PD98059 or U0126 as indicated,
cell lysates were processed for western blotting for the band patterns of KLF8. Total ERK, pERK
-actin were included as controls. For the dose-dependent study the treatment time was 4
G) The catalytic
activity of ERK2 is the phosphorylation of KLF8 at the S48 site. Myc-tagged ERK2 or its
dominant-negative mutant K54R was overexpressed in the MCF7-K8 or MCF-K8S48A cells.
Lysates were prepared after 48 hours for western blotting. (H) ERK2 interacts with KLF8 in an
S48-dependent manner. Indicated KLF8, its mutant or vector control was overexpressed in
HEK293 cells and precipitated with anti-HA antibody from cell lysates prepared after 48 hours.
Co-precipitated ERKs were analyzed by western blotting. (I) ERK2 activity is required for EGFstimulated phosphorylation of KLF8. The MCF7-K8 cells were transfected with dominantnegative ERK2 mutant K54R plasmid or vector alone. After 36 h, the cells were serum-starved
for 16 h and then treated with 50 ng/ml EGF or DMSO. Cell lysates were collected after 30
minutes for western blotting. (J) ERK2 activity is sufficient for the phosphorylation of KLF8. The
MCF7-K8 cells were transfected with the ERK2 constitutive active mutant (ERK2-CA). After 36
western blotting.
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Figure 6. Phosphorylation of KLF8 at the S48 site is critical for KLF8 stability.
(A)The unphosphorylated KLF8 mutant proteins express at a decreased level. Indicated HAtagged KLF8 and its mutants were overexpressed in HEK293 cells for 48 h prior to preparation
-actin antibodies and quantification of protein
expression. (B, C) The unphosphorylated KLF8 mutant proteins have a shortened lifespan.
Indicated HA-KLF8 and its mutants were overexpressed in HEK293 cells for 36 h. CHX drug
was then added and cell lysates were collected at eh indicated time points for western blotting
and protein quantification.
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Figure 7. The phosphorylated form of KLF8 acts as a mask to protect the overall
stability of KLF8 protein.
(A, B) The phosphorylated form of KLF8 protein degrades to protect the unphosphorylated form.
The MCF7-K8 and MCF7-K8-S48 cells were subjected to CHX chase assay as described
above. The upper and lower bands of the wild-type KLF8 were quantified separately and
compared to total expression of the wild-type KLF8 as well as the S48A mutant protein. (C, D)
The lifespan of the unphosphorylated form of KLF8 protein decreases in the absence of the
phosphorylated form. The CHX chase assay was carried out similarly except that the MCF7-K8
cells were treated with the MEK inhibitor U0126 inhibitor before and during the chase assay as
described in the Experimental Procedures.
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Figure 8. The phosphorylation at the S48 is essential for KLF8 to promote cell
migration
The MCF7-K8 (WT), MCF7-K8-S48A, MCF7-K8-S48D alongside the mock control cells were
grown and subject to wound closure (A, B) as well as Boyden chamber (C) migration assays as
described in the Experimental Procedures.
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Figure 9. Proposed model of the mechanism of action
ERK2 phosphorylate KLF8 at the S48 site. This phosphorylation distracts KLF8 degradation of
unknown mechanism away from the unphosphorylated form towards the phosphorylated form of
the protein, resulting in an increase in overall stability of the KLF8 protein. On the other hand,
the ERK2 phosphorylation of KLF8 is balanced by two potential counteracting mechanisms of
regulation mediated by the inhibitory R-N-R motif and the supporting D-P-P-E motif.
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Table 1. Sequences of primers and oligonucleotides used
Primer name

Primer sequence (5’ – 3’)

pKH3-F

CCC AAG CTT CTG CAG GTC G

pKH3-R

GGA CAA ACC ACA ACT AGA ATG CAG

KLF8 d11-20-R

CCT GCA T TG AGT TGT T TA TGA GTT TAT CC

KLF8 d11-20-F

AAC AAC TCA ATG CAG GTA TTC AAG C

KLF8 d21-30-R

CGA ACA GAG CCA CCT TCT GAA TTA AGT T

KLF8 d21-30-F

AGG TGG CTC TGT TCG GAA CAG AGA TC

KLF8 d31-40-R

CTG TAT TCA GCA GTG ACC TGC TTG AAT A

KLF8 d31-40-F

TCA CTG CTG AAT ACA GAA GTA ATA TGA CT

KLF8 d41-50-R

ATC CAG GAG TAT CTC AGG GGG ATC TCT

KLF8 d41-50-F

TGA GAT ACT CCT GGA TGC CAA CCC CAT

KLF8 S31A-R

CCG AAC AGC AGC AGT GAC CTG

KLF8 S31A-F

ACT GCT GCT GTT CGG AAC AGA GAT C

KLF8 Y42A-R

ACT TCT GGC TTC TAT CTC AGG G

KLF8 Y42A-F

ATA GAA GCC AGA AGT AAT ATG ACT TCT CC

KLF8 S44A-R

CAT ATT AGC TCT GTA TTC TAT CTC AGG G

KLF8 S44A-F

TAC AGA GCT AAT ATG ACT TCT CCA ACA

KLF8 T47A-R

TGG AGA AGC CAT ATT ACT TCT GTA TTC

KLF8 T47A-F

AAT ATG GCT TCT CCA ACA CTC CTG

KLF8 S48A-R

TGT TGG AGC AGT CAT ATT ACT TCT

KLF8 S48A-F

ATG ACT GCT CCA ACA CTC CTG GAT
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Primer name

Primer sequence (5’ – 3’)

KLF8 T50A-R

CAG GAG TGC TGG AGA AGT CAT ATT

KLF8 T50A-F

TCT CCA GCA CTC CTG GAT GCC

KLF8 S48D-R

TGT TGG ATC AGT CAT ATT ACT TCT GTA

KLF8 S48D-F

ATG ACT GAT CCA ACA CTC CTG GAT

KLF8 d31-35-F

ACT GCT GAT CCC CCT GAG ATA GAA

KLF8 d31-35-R

AGG GGG ATC AGC AGT GAC CTG CTT

KLF8 d36-40-F

CGG A CGG AAC AGA GAA TAC AGA AGT AAT ATG AC
AGA

KLF8 d36-40-R

TCT GTA TTC TCT GTT CCG AAC AGA AGC

KLF8 P37A-R

TAT CTC AGG GGC ATC TCT GTT CCG

KLF8 P37A-F

AGA GAT GCC CCT GAG ATA GAA TAC

KLF8 P38A-R

TAT CTC AGC GGG ATC TCT GTT CCG

KLF8 P38A-F

AGA GAT CCC GCT GAG ATA GAA TAC

KLF8 P37/38A-R

TAT CTC AGC GGC ATC TCT GTT CCG

KLF8 P37/38A-F

AGA GAT GCC GCT GAG ATA GAA TAC

KLF8 D36A-R

AGG GGG AGC TCT GTT CCG AAC AGA

KLF8 D36A-F

AAC AGA GCT CCC CCT GAG ATA GAA

KLF8 E39A-R

TTC TAT CGC AGG GGG ATC TCT GTT

KLF8 E39A-F

TCC CCC TGC GAT AGA ATA CAG AAG

KLF8 D36/E39A-R

TTC TAT CGC AGG GGG AGC TCT GTT

KLF8 D36/E39A-F

AAC AGA GCT CCC CCT GCG ATA GAA
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Primer name

Primer sequence (5’ – 3’)

KLF8 I40A-R

GTA TTC TGC CTC AGG GGG ATC TCT

KLF8 I40A-F

CCT GAG GCA GAA TAC AGA AGT AAT

KLF8 I40R-R

GTA TTC TCT CTC AGG GGG ATC TCT

KLF8 I40R-F

CCT GAG AGA GAA TAC AGA AGT AAT

ERK2-SmaI-F

TTT CCC GGG AGC AGC TGC GGC GGC GGC GGG
CGC

ERK2-ClaI-R

CCC ATC GAT TTA AGA TCT GTA TCC TGG CTG GAA
TC

ERK2 K54R-F

GCT ATC AGG AAA ATC AGC CCC TTT

ERK2 K54R-R

GAT TTT CCT GAT AGC TAC TCG AAC

ERK2 R67S-F

TGC CAG AGC ACC CTG AGG GAG ATA

ERK2 R67S-R

CAG GGT GCT CTG GCA GTA GGT CTG

ERK2 D321N-F

CCG AGT AAC GAG CCC ATC GCC GAA

ERK2 D321N-R

GGG CTC GTT ACT CGG GTC GTA ATA
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CHAPTER 3: KLF8 PROMOTES SYSTOLIC DYSFUNCTION THAT
LEADS TO SEVERE DILATED CARDIOMYOPATHY IN KLF8
TRANSGENIC MOUSE MODEL

Abstract

Krüppel-like factor 8 (KLF8) is highly expressed in several types of human cancers. Our
previous studies have demonstrated that KLF8 as a dual transcription factor promotes
tumor formation and metastasis by up- or down-regulating several transcriptional targets
including cyclin D1, MMPs, EGFR, EPSTI1 CXCR4, KLF4, E-cadherin, microRNA-146a
and microRNA-141. KLF8 has also been reported to play a critical role in DNA repair,
adipogenesis, preeclampsia, zebrafish development and Alzheimer’s disease. KLF8’s
role in cancer has been studied primarily in vitro and in xenograft mouse models. To
better understand KLF8’s function in vivo in a physiologically relevant context, we
generated conditional KLF8 transgenic mouse model to investigate role of KLF8 in
spontaneous tumorigenesis. Surprisingly, global induction of expression of the
transgene caused postnatal early death of all the mice with significantly enlarged heart.
Further timespan ultrasound echocardiograph studies revealed that KLF8 induces
systolic dysfunction from as early as one month of age that leads to fatal dilated
cardiomyopathy causing early death. Excitingly cardiomyocyte specific induction of
KLF8 expression demonstrated identical phenotypes, thereby suggesting that KLF8
overexpression in cardiomyocyte leads to dilated cardiomyopathy. Studies on the
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underlying molecular mechanisms are in progress including identifying KLF8 regulated
mRNA and miRNA targets in cardiomyocyte to reveal the mechanism behind KLF8
mediated cardiomyopathy. Overall this study identifies a novel role of KLF8 in
cardiomyopathy, one of the leading causes of cardiac death and provides insight into
the responsible mechanism that will advance the cardiac research field to invent new
therapeutics for this deadly disease.

Introduction

Kruppel like factor 8 is a dual transcription factor critical for cell cycle regulation,
oncogenic transformation, cancer cell invasion, migration and metastasis in different
types of cancer[2, 4, 5, 7, 21, 23]. Other than cancer its involvement in other cellular
functions like DNA repair[16], developmental role in preeclampsia[44, 45], Alzheimer’s
disease[47], adipogenesis[48], cerebellar development in zebrafish[46] have been
recently elucidated. Most of the studies with KLF8 have been carried out in vitro and
xenograft models, whereas its function in vivo in a better physiological context remains
unexplored. As KLF8 is known to actively promote different cancer progression [4, 6,
27, 39, 189, 190], it is absolutely critical to assess its role in vivo to establish KLF8 as a
therapeutic target for cancer and other relevant diseases. Genetically engineered
mouse model is the most important tool to evaluate function of a gene in vivo [52, 56,
61, 191]. Currently the only KLF8 genetically engineered mice available is a KLF3/KLF8
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double knock out mice where KLF8 is knocked out by gene trap method[192]. This
study demonstrated these double knockout mice were embryonic lethal with decreased
expression of beta-globin without further mechanistic approach which limits us to
understand the role of KLF8 in vivo in different tissues clearly. To explore KLF8 function
in vivo, we constructed a conditional KLF8 transgenic mouse model induced by CreloxP recombination as KLF8 is found in elevated level in different cancers. This is the
first transgenic mouse model of KLF8 to our knowledge and provides a better tool in
understanding role of KLF8 in vivo. As being equipped with a Cre-loxP system, these
model also present immense potential of exploring KLF8 function in different tissues
specifically. We also constructed the first Cre based KLF8 knock out mouse model to
study its role in parallel.

Our primary aim was to investigate KLF8 mediated spontaneous tumorigenesis
in these mice as KLF8 has been implied mostly in different cancers including breast,
ovarian, gastric, liver, renal, glioma, osteosarcoma, oral, nasopharyngeal carcinoma,
bladder, prostate and bladder cancer[2]. In view of this widespread role of KLF8 in
various cancers, before evaluating mammary specific KLF8 transgenic mice, we
decided to construct KLF8 global transgenic mice to initiate KLF8 overexpression in
germ line distributing to all different tissues. The first striking observation was significant
higher postnatal death in the KLF8 global transgenic mice. Necropsy of these mice
revealed increased heart size which later proved to be dilated cardiomyopathy in
presence of KLF8 overexpression and thus discovering a novel role of KLF8 in cardiac
function. In parallel, the reverse cardiac phenotype was observed in the KLF8 KO mice,
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thereby suggesting a critical role of KLF8 in cardiac tissue. Overall this study gives
mechanistic insight into an unknown novel role of KLF8 in dilated cardiomyopathy.

Cardiomyopathy, the primary disease of heart muscle is a leading cause of heart
failure and death[193]. It can happen in spite of any age, condition and background.
Severe cardiomyopathy causes irreversible damage to heart which further aggravates
the disease. There are mainly three subtype of cardiomyopathy; dilated cardiomyopathy
[97,

194,

195],

hypertrophic

cardiomyopathy

[145,

146]

and

restrictive

cardiomyopathy[151, 196] while the first two have been studied the most due to their
high occurrence. Hypertrophic cardiomyopathy is the leading cause behind sudden
cardiac arrest. In this type of cardiomyopathy, size of heart muscle cells cardiomyocytes
enlarge in width as sarcomeres are added widthwise, enhancing increase in heart
posterior wall and intraventricular septum thickness. Thickening of wall in hypertrophic
cardiomyopathy causes abnormal filling of left ventricle and diastolic dysfunction which
leads to increase in blood pressure, cardiac stiffening and sudden cardiac arrest [143,
145, 146, 197, 198]. In contrast dilated cardiomyopathy causes increase in the ventricle
size. Dilation of heart generally initiates from left ventricle and spreads out to atria and
right ventricle during severity. The stretch in heart muscles causes the enlargement of
the left ventricle leading to dysfunction in pumping out blood throughout body. Severity
of this cardiomyopathy is directly proportional to decrease in cardiac output and finally
leads to death [97, 117]. The underlying mechanism behind dilated cardiomyopathy is
not clearly understood till date. Both inheritance of a genetic signature or effect of
environment like stress, alcohol, toxin, diabetes can lead to dilated cardiomyopathy
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[108]. Current treatments are limited to beta-blocker, ACE inhibitor, ARB, and diuretics
drug based prevention of further heart dilation and heart transplant in extreme
conditions. Further mechanistic studies are necessary to get an insight on the molecular
mechanism behind this disease to find a better therapeutic target in cure of heart failure.

In this current study we established the first KLF8 transgenic mouse model and
further exploring these mice, we demonstrated a novel role of KLF8 in dilated
cardiomyopathy. We also identified KLF8 overexpression in cardiomyocytes, initiates
systolic dysfunction leading to severe dilated cardiomyopathy in transgenic mouse
models. Ongoing studies are focused to discovering the KLF8 mediated signaling link
causing this cardiomyopathy in molecular level.
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Materials & Methods

KLF8 transgene plasmid construction

pTraffic plasmid was obtained from Dr. Lydia Matesic (University of South
Carolina).dEGFP-F and dEGFP-R primers were used to delete the eGFP gene from this
plasmid. TGL-F and R primer were used to amplify TGL coding sequence from SFGnesTGL vector.

THE TGL sequence was cloned into pTraffic vector after deleting

EGFP to construct pTraffic-nesTGL vector. pTraffic-nesTGL vector was digested by
AscI and ClaI as a host plasmid and pKH3-KLF8 plasmid was digested with SalI and
ClaI to release HA tagged KLF8. Both the AscI site on the vector and Sal1 site were
blunted by klenow enzyme treatment. Later on we also deleted the T sequence to get
pTraffic-KLF8-nGL transgenic construct. The nes sequence exports GFP and luciferase
to cytoplasm to negate any interference on KLF8 function. The luciferase expression
provides us a non-invasive quantitative tool to visualize transgene expression in vivo.
There is a secondary ribosome binding site, IRES after KLF8 to initiate protein
translation under the same transcript. Overall, pTraffic-KLF8-Gl (KLF8 transgene)
plasmid has been constructed to promote KLF8 overexpression. For tissue specific
expression loxP flanked STOP codon has been incorporated upstream of KLF8. The
plasmid consists of a CAG promoter, a combination of the cytomegalovirus (CMV) early
enhancer element and chicken beta-actin promoter. This promoter is used for high gene
expression in mammalian cell. The CAG promoter is followed by a loxP-dsRed2-STOP63

loxP cassette. This cassette is followed by human KLF8 cDNA tagged with 3 HA tags in
the N terminal. After the KLF8, there is IRES (Secondary ribosome binding site) and a
fused GFP and Luciferase cDNA. This circular plasmid was digested with SspI and SfiI
restriction endonucleases to cleave the SV40-Amp region. The SV40-Amp region is not
required for transgenic DNA microinjection. So the digestion gives rise to a 10.5 kbp
linear fragment which will be used to generate transgenic mouse line.

Transfection, Fluorescence Microscopy and Luciferase activity

Transfection was performed in HEK293 and MEF cells as with lipofectamine 2000
reagents as mentioned before. After 48 hrs of transfection, cells were observed under
fluorescent microscope in both RFP and GFP channels. Luciferase assay was
performed as described before.

Construction of KLF8 transgenic mouse models

The linearized KLF8 transgene pTg-K8-GL(Fig. S1) was injected directly into the
pronucleus of a newly fertilized mouse (B6 strain) egg to generate floxed KLF8
transgenic by University of Michigan, transgenic mouse facility. We optimized a taqman
real time PCR method to detect 0.01 copy no of plasmid DNA in a pool of WT mouse
genomic DNA. Plasmid DNA was mixed in different copy no ratio with WT mouse
genomic DNA and qPCR was done with pTgK8 primer and R2 value of 0.98
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demonstrated the efficacy of this protocol. After we identified the B65-Floxed-KLF8 Tg
mice;

we

crossed

4

separate

founders

with

homozygous

FVB/N-TgN(EIIa-

Cre)C5379Lmgd (Jackson lab stock 003314 ; This line carries a Cre transgene under
the control of the adenovirus EIIa promoter that targets expression of Cre recombinase
to the early mouse embryo) mice. The offsprings were of mixed FVB.B65 background
including the Cre control and KLF8-gTg mice.

Genotyping

We collected genomic DNA (Promega genomic DNA extraction kit; A1120), RNA
(Trizol) and Protein (SDS sample buffer) from mice tails using liquid nitrogen based
homogenization. Genomic DNA was used for PCR with LoxP-F (5’-AGG ACT ACA CCA
TCG TGG AGC-3’), pTg-K8-F (5’-TTC GGC TTC TGG CGT GTG ACC-3’) and pTg-K8R (5’-TGG CAT CCA GGA GTG TTG GAG-3’) primers. These primers are designed to
detect the KLF8 transgene. Lox-P forward primer and pTg-K8 reverse primer will give
rise to an amplification of 601 bp without Cre recombination and there will be no
amplification after Cre recombination as this forward primer is designed on the loxP
flanked site, which will be excised by Cre. The pTg-K8 forward and reverse primer will
give rise to an amplification of 1393 bp fragment without Cre and 400 bp after Cre
recombination. Genotyping was done by genomic DNA PCR with pTg-K8 F, pTg-K8-R
primer, RT PCR for RFP ( RFP-RT-F 5’-GTC ATC ACC GAG TTC ATG CG-3’; RFP-RTR 5’-ACC TTG GAG CCG TAC TGG AA), GFP (eGFP-RT-F 5’-TGA ACT TCA AGA
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TCC GCC ACA-3’; eGFP-RT-R 5’-TTC TCG TTG GGG TCT TTG CT-3’), HA-K8 (HA-F
5’-tccagattacgctggatcc-3’, HA-K8-R 5’-ttggcatccaggagtgttg-3’) primers. Western blot
was also done with tail lysates for HA-KLF8, GFP and RFP expression. For tissue
specific KLF8 expressing mice, tail genomic DNA was used in PCR with pTg-K8-F/R
primer and Cre-F/R primer to evaluate presence of transgene and Cre in tail DNA. Mice
having both were characterized as positive transgenic mice, whereas the other three
possibilities will produce floxed control, cre control and WT control mice.

Bio-Luminescence Imaging

The mice were anaesthetized using isoflurane and injected intraperitoneally with DLuciferin in phosphate buffer (30 mg/kg mouse weight). D-Luciferin solution is light
sensitive and kept in -20C for long term storage. It should be aliquoted to prevent
freeze-thaw cycles. Mice hair was removed from the area of interest. We applied eye
ointment to the mouse eyes to protect them from UV light during imaging.
Luminescence and GFP channel fluorescence were imaged by IVIS50 to investigate
efficacy of transgene expression in vivo.

Ultrasound Echocardiograph and hemodynamic analysis

The Visual Sonics VEVO 2100 echocardiography machine is turned on along with the
oxygen generator to ensure the oxygen supply. The ultrasound gel warmer is turned on
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before to pre-warm the gel. Mouse handling pad is warmed and maintained in 37c
throughout the procedure. Mice are anesthetized with isoflurane (1-2%). The
anesthetized mouse is secured to an animal handling platform in supine position with its
nose covered by a cone with constant supply of 1-2% isoflurane to maintain anesthesia.
Mouse paws are secured to the electrode pads with conductive gel (SIGNAGEL®
Electrode Gel – Parkers Laboratories) to asses ECG. A rectal probe is also used to
overall ensure 37c body temperature and respiration rate for physiological assessment
during imaging. Depilatory (hair removing) crème is applied on the mouse chest and
upper abdomen area for couple of minutes. All hair in those areas is removed by
sterilized cotton buds and further cleaned to remove any trace of remaining hair. Prewarmed ultrasound gel (Aquasonic clear ultrasound gel – parker Laboratories) is
applied on the mouse chest and cotton buds are used to get rid of the bubbles. 40 MHz
transducer (ultrasound probe) of the Visual Sonics VEVO 2100 echocardiography
machine is moved gently on the mouse chest with gentle pressure to find the long axis
view of LV. VEVO 2100 machine is used to record both B mode and M mode images of
the left ventricle in long axis region and then the probe is rotated to obtain the
parasternal short axis view of LV. The M mode images are used for further
measurements. After recording all the images, the mouse is cleaned with a sterilized
wipe and returned to its cage. The cage is kept on a heating pad to help the mouse
regain consciousness. The mouse is monitored following days to ensure no side effects
of this procedure. M mode images were analyzed by VEVO 2.1 software.
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Organ collection and preparation

Different organs were collected after necropsy of mice. Collected organs were stored in
formalin solution in 4C after PBS wash. Different organs were paraffin processed
overnight by paraffin in Leica processor. After embedding into tissue blocks, these
organs were sectioned @ 7um size of tissue which was utilized further for different
staining.

H&E and Masson’s Trichrome Staining

Paraffin processed tissue slides were baked @ 65° C for 20 minutes to melt paraffin.
Dehydration procedure was done by treatment with Xylene twice for 10 minutes, 100%
EtOH twice for 5 minutes each, 95% ethanol for 5 mins followed by 15 dips in 70%
ethanol and 50% ethanol. After air drying, the slides were stained with filtered Mayers
Hematoxylin for 3 mins followed by a treatment with 0.2% NH4OH for 30 sec-1min
depends on the required blue color intensity. The slides were rinsed in cool running
ddH2O for 5 minutes and stained with Eosin (0.5% in 95%EtOH) 12 times. These slides
are quickly rinsed and rehydrated by treatment with 50% EtOH 10 times, 70% EtOH 10
times, 95% EtOH for 30 seconds and equilibrate in 100% EtOH for 1 minute. Permount
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solution was used to mount the slides after final xylene wash. Masson’s trichrome
staining was done with sigma HT-15 kit and following the manufacturer protocol.

qPCR and Western Blot

Trizol was used to isolate both RNA and protein from different mouse organs after liquid
nitrogen based homogenization. Thermo fisher maxima 1st strand synthesis kit was
used to reverse transcribes mRNA and qPCR was performed with Sybr green in
ABI7900 HT equipment. Both qPCR and western blot was done according to our
previously published protocols.

Immunohistostaining

Paraffin embedded tissue were used for immunohistostaining. The detailed procedure is
described previously[199]. HA antibody was used 1:200 ratio.

Cardiovascular disease mRNA and miRNA PCR array

KLF8-hTg mice hearts were collected along with floxed control mice. Similar position of
the left ventricle was extracted and stored in -80C to protect RNA integrity. Liquid
nitrogen was utilized to homogenize the heart tissues, and mRNA was isolated by trizol
based method whereas micro RNAs were isolated by miReasy kit. Both mRNA and
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miRNA were reverse transcribed using their respective reverse transcriptase kit from
qiagen to negate genomic DNA contamination. A master mix was prepared with SyBr
green, cDNA and water and 20 ul of this was added into each well of one array plate
(SA biosciences PAMM-174Z and MIMM-113Z). The result was analyzed by SA
bioscience software.

Isolation of primary cardiomyocytes

5 days old mice were sacrificed after confirming transgene expression by BLI. Heart
was quickly extracted and cleaned with HBSS buffer. Primary cardiomyocyte was
isolated using Pierce primary cardiomyocyte isolation kit (Thermofischer 88281).
Spontaneous beating of cardiomyocytes was observed after 7 days of culture.
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Results

Construction of Global KLF8 Transgenic Mice

To investigate KLF8 role in vivo, we started generating KLF8 transgenic mice. Although
our primary aim was to identify mammary tumor formation mediated by KLF8, we first
made global KLF8 transgenic mice to assess the role of KLF8 in any other potential
diseases. In order to generate the transgenic mice, we first constructed pTraffic-KLF8GL plasmid with HA tagged KLF8 transgene under a CAG promoter [78, 79], a
combination of the cytomegalovirus (CMV) early enhancer element and chicken betaactin promoter. The plasmid mapping includes a CAG promoter followed by a loxPdsRed2-STOP-loxP cassette upstream of N terminal 3 HA tagged human KLF8, IRES
(Secondary ribosome binding site) and a fused GFP-Luciferase gene (Fig 10A). Creloxp mediated recombination will promote HA tagged KLF8 expression and a RFP to
GFP-Luciferase switch by excising the loxp-flanked RFP and STOP codon. To validate
the efficacy of this transgene in vitro, the linearized plasmid was transfected into 293FT
cells with and without Cre recombinase expressing plasmid co-transfection. Expectedly,
Cre mediated recombination showed an evident RFP to GFP switch by fluorescence
microscopy (Fig 10B); induction in HA-KLF8, GFP expression in western blot (Fig 10C)
and increased luminescence activity (Fig 10D) in 293 and MEF (Data not shown) cells.
After confirming the plasmid efficacy, linearized pTg-KLF8-GL plasmid was injected
directly into the pronucleus of a newly fertilized mouse (B6 strain) egg by University of
Michigan, transgenic mouse facility. We designed a standardized genotyping protocol to
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genotype these founder floxed mice. To increase the efficacy of this test, transgenic
plamid was mixed with wild type mouse genomic DNA in different copy numbers starting
from as low as 0.1 copy. Two different primers were used to investigate if low copy no of
transgene when masked in genomic DNA, can be detected. Genomic DNA PCR could
identify till 1 copy no of transgene (Fig. 11A-C). To further make this genotyping test
more productive, we decided to use taqman qPCR assay as it uses a third specific
probe alongside two primers. We used this taqman qPCR to perform the similar
experiment and excitingly this method was observed to be able to detect till 0.01 copy
no of transgene (Fig 11E). We plotted all this different copy no of transgene CT values
in a standard curve which came out to be very significant with a R 2 value of 0.97 (Fig
11F). Upon receiving the offspring mice from University of Michigan transgenic facility,
we genotyped these mice by our standardized taqman real time PCR to identify the
positive mice which harbored the loxp-flanked transgene (Fig 12A-B). We also used
genomic DNA PCR from tail snip DNA to detect the presence of the transgene (Fig 12
C), RFP expression in tail snips by fluorescence microscopy (Fig 12D) and western blot
to detect RFP expression (Data not shown). The founder mice with loxp-flanked
transgene were named as B65-Floxed-KLF8-Tg. We backcrossed two of the founder
lines (one with high transgene copy no and one with medium transgene copy no) with
FVB WT mice to obtain pure FVB strain floxed-KLF8 mice which would be more
relevant for breast cancer studies. We decided to over express KLF8 globally primarily
to investigate role of KLF8 in promoting oncogenesis in various tissues as KLF8 have
been implicated in a large array of cancer types. To induce KLF8 transgene expression
globally, we crossed 4 separate founder B65-Floxed-KLF8-Tg mice with homozygous
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FVB/N-TgN(EIIa-Cre)C5379Lmgd (Jackson lab stock 003314 ; This line carries a Cre
transgene under the control of the adenovirus EIIa promoter that targets expression of
Cre recombinase to the early mouse embryo) mice[85] (Fig 14A). The offsprings were of
mixed FVB.B65 background including the Cre control and transgenic mice with global
KLF8 expression (FVB.B65-KLF8-gTg). The KLF8-gTg mice were genotyped by
Bioluminescence Imaging, genomic DNA PCR (Fig 15) for the transgene, real time PCR
for RFP, GFP, HA-KLF8 expression and western blot for HA-KLF8 expression. KLF8gTg mice showed high luminescence compared to Cre control in whole body BLI (Fig.
14B). Organ specific BLI (Fig. 14C) demonstrated distribution of KLF8 transgene
expression globally in all tissues including heart, lung, liver, muscle, brain and kidney.
Real time PCR with universal KLF8 primer showed increase in KLF8 expression in
different tissues of KLF8-gTg mice compared to littermate Cre controls (Fig 14D).
Further overexpression of KLF8 and GFP in KLF8-gTg mice heart was confirmed by
western blot (Fig 14E). Overall these result demonstrated successful construction of
global KLF8 transgenic mice (KLF8-gTg) which was used further in this study to
investigate any potential unknown function of KLF8 in vivo.
KLF8 global transgenic mice (KLF8-gTg) showed increased heart size and decreased
survival rate

In order to identify any critical phenotypical differences, KLF8-gTg mice were observed
against the littermate Cre control mice. KLF8-gTg mice and its littermate controls were
in mixed background (B65-Floxed-KLF8 X FVB-EIIA-Cre). We observed that KLF8-gTg
mice started dying from a very early age (5 months) with hair loss and lethargic
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condition. Overall survival analysis of these mice by Kaplan-Meier plot revealed that
KLF8-gTg mice had significantly lower survival (higher mortality) rate compared to the
littermate controls with a Z score of 7.32 (Fig 16A). Interestingly, all of the transgenic
mice died by 16-20 months of age much earlier than the littermate control mice. This
higher mortality rate was observed in both transgenic male and female mice whereas in
male mice it was slightly higher than the female mice (Fig 16B). To unveil the cause of
this sudden death of KLF8-gTg mice, we performed necropsy and strikingly found these
mice having enlarged hearts compared to their littermate controls (Fig 16C-D). Most of
the transgenic mice with enlarged heart were also observed to have increased lung size
(Fig 16C-E). Almost all KLF8-gTg mice died early showed this striking cardiac
phenotype (Fig 17). As the heart phenotype seemed to be the likely cause of the
sudden death in transgenic mice, we also observed decrease in transgenic mice body
weight compared to littermate controls (Fig 16F) which reasserts the lean phenotype
observed of these mice in BLI (Fig 18). We also observed other tissues in KLF8-gTg
mice and compared whole mount organ and tissue morphology with its negative
littermate controls. We didn’t find any significant phenotype in KLF8-gTg mice brain,
lung, liver, spleen, muscle etc (Fig 19 A,C-G). Further necropsy demonstrated that
KLF8-gTg mice had significantly lower fat mass in gonadal depots attached to the
epididymis and testes in males and the uterus and ovaries in females compared to the
negative controls (Fig 19B,I and Fig 20A-C), which uncovered the mystery behind the
decrease in transgenic mouse body weight. H&E staining of the abdominal white
adipose tissue showed that the KLF8-gTg mice had significantly smaller adipocyte cells
(Fig 20D) suggesting these mice might develop lipoatrophy. KLF8-gTg mice didn’t show
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any significant difference in food intake compared to the littermate controls (Fig 20E),
which excluded any effect of food consumption difference on the body weight change
phenotype. Along with white adipose tissue difference, we also observed less brown
adipose tissue in the KLF8-gTg mice (Fig 21A-B). As the cardiac phenotype was most
likely the cause of early death in transgenic mice, we confirmed KLF8 overexpression in
transgenic mice heart tissue (Fig 16G). Overall, we discovered two novel phenotypes in
the global KLF8 transgenic mice causing early death. Further mechanistic studies are
required to establish if the decrease in fat mass phenotype is a consequence of the
cardiac phenotype or an unrelated novel phenotype observed in these KLF8-gTg mice.

Global expression of KLF8 induces dilated cardiomyopathy in transgenic mice

As previous results suggested the cardiac phenotype to be possible cause of early
death in global KLF8 transgenic mice, we stained the mice hearts with masson’s
trichrome staining to investigate cardiac fibrosis which is a positive indicator of heart
failure. KLF8-gTg mice was found to have significantly increased cardiac fibrosis,
predominantly in the ventricular walls (Fig 22A-B) compared to the Cre littermate
controls which further validated heart failure as the reason behind the higher mortality
rate in these transgenic mice. Fig 23 demonstrates representative images of increased
myocardial fibrosis in KLF8-gTg mice. Moreover significant increased heart failure
associated marker genes; b-MHC, ANP and BNP expression in KLF8-gTg mice hearts
(Fig 22C-E) suggested global overexpression of KLF8 induces cardiomyopathy in
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transgenic mice. To characterize the cardiomyopathy observed in these transgenic
mice, hemodynamic analysis was performed by ultrasound echocardiography starting at
10 months of age. B mode images from ultrasound echocardiograph clearly showed
increase of left ventricular cavity size in KLF8-gTg mice (Data not shown).
Hemodynamic analysis from the M mode results (Table 2) revealed that KLF8 global
transgenic mice had significant increase in left ventricle inner diameter both at systole
and diastole (Fig 22F-H). In addition, the KLF8-gTg mice also showed significant
decrease in left ventricular function with sharp decline in ejection fraction and fractional
shortening (Fig 22I,J). We didn’t observe any significant change in KLF8-gTg mice
intraventricular septum and left ventricular posterior wall diameter which excludes the
possibility of hypertrophic cardiomyopathy. Overall the ultrasound echocardiograph
results revealed that KLF8-gTg mice have significant dilation in left ventricle cavity and
decrease in left ventricular function which is a characteristic of dilated cardiomyopathy.
The dilated cardiomyopathy disease progressed aggressively in KLF8-gTg mice as we
observed significant increase in LV diameter at systole and diastole and severe
deterioration in ejection fraction and fractional shortening after 3 months from the first
ultrasound echocardiograph. Negative control littermate didn’t show any significant
difference in cardiac parameters in this duration (Fig 24-25). We also did Tunel assay to
assess apoptotic cardiomyocyte to investigate the cardiac injury by this disease in
KLF8-gTg mice. Results from this experiment clearly showed increased cardiomyocyte
apoptosis in KLF8-gTg mice hearts compared to negative control mice (Fig 26). We
sub grouped the KLF8-gTg mice into medium and high KLF8 expressing mice based on
their transgene expression (Data not shown) to investigate dose dependent effect on
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KLF8 on dilated cardiomyopathy in these transgenic mice. Strikingly, the KLF8-gTg
mice with high transgene expression showed more severe left ventricular dilation and
cardiac dysfunction compared to the medium KLF8 expressing mice group (Fig 27A-D,
Table 3). This strong positive correlation between KLF8 expression and cardiac
dysfunction strengthen our hypothesis that KLF8 promotes dilated cardiomyopathy
causing early death in transgenic mice in both male and female.

KLF8 induces systolic dysfunction which leads to dilated cardiomyopathy in KLF8 global
transgenic mice

Dilated cardiomyopathy is associated with both systolic and diastolic dysfunction.
Systolic dysfunction is defined as decrease in myocardial contractility whereas diastolic
dysfunction is characterized by abnormal filling of left ventricle. The previous
echocardiograph of the KLF8-gTg mice started from 9 months of age showing increase
in left ventricular inner diameter both at systole and diastole limiting our knowledge
about the underlying cause of this KLF8 induced dilated cardiomyopathy. To investigate
the progression of the disease, we started time point hemodynamic analysis with KLF8gTg mice from one month of age. As our B65-Floxed-KLF8 mice were being
backcrossed with FVB WT mice to construct pure strain of FVB.B65-Floxed-KLF8-Tg
mice,

the second group of KLF8-gTg mice constructed was of FVB background.

Interestingly, ultrasound echocardiograph showed increase in left ventricular diameter
only at systole and associated decrease in ejection fraction, fractional shortening in
KLF8-gTg mice from 1 month of age whereas, no change was observed in left
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ventricular diastolic diameter at that early age (Fig 28A-E). Strikingly, increase in
diastolic diameter and dilation of left ventricle in transgenic mice were observed from 3
months of age with further deterioration in left ventricular dysfunction causing early
death in these mice. Overall this result revealed that KLF8 promotes systolic
dysfunction characterized by increase in left ventricular systolic diameter and decline in
fractional shortening first at a very early age (from 1 month) which eventually leads to
severe dilation of heart identifying systolic dysfunction as the mediator of this KLF8
induced dilated cardiomyopathy.

Interestingly, FVB background mice started dying

earlier compared to FVB.B65 mixed background mice but independent of strain
background, the KLF8-gTg mice died much earlier compared to the negative Cre control
mice (Fig. 29), which reasserts this novel cardiac phenotype induced by KLF8. Both
these strain of mice demonstrated similar cardiac and fat phenotypes (Fig. 30A-B).
These results were further used to interpret the increase in lung size phenotype
observed in KLF8-gTg mice (Fig. 16C) as probable pulmonary edema which is a known
associated phenotype with systolic dysfunction. Based on these findings, we
hypothesized that KLF8 might be critical for myocardial contractile function as
overexpression

of

KLF8

causes

systolic

culminating into fatal dilated cardiomyopathy.
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dysfunction

(contractile

dysfunction)

Construction of cardiomyocyte specific KLF8 transgenic mice

Previously in this study we have discovered KLF8 overexpression globally stimulates
systolic dysfunction leading to severe dilated cardiomyopathy in transgenic mice. As
KLF8 was overexpressed globally in the KLF8-gTg mice, it is difficult to interpret the
functional link of KLF8 to this disease in molecular basis. To address the unknown
molecular mechanism behind KLF8 mediated cardiomyopathy, we started constructing
cardiomyocyte specific KLF8 transgenic mice as cardiomyocyte is the foremost cells in
making up cardiac muscle. To construct these mice, FVB-B6-floxed-KLF8 (7th
generation) mice were crossed with cardiomyocyte specific B6-FVB-Tg-Myh6-Cre [5].
The offsprings were of FVB.B65 mixed strain and consisted four different groups
including KLF8 cardiomyocyte specific transgenic mice named as KLF8-hTg, floxed
control, Cre control and WT control mice (Fig. 31A). Genomic DNA was isolated from
mice tails and we did PCR with pTg-K8-F and pTg-K8-R primer to investigate the
transgene incorporation into genome and with Cre-F and Cre-R to investigate presence
of Cre transgene. Heart specific transgene expression in the KLF8-hTg mice was
validated by Bio luminescence Imaging (Fig 31B). Further qPCR with universal KLF8
primer confirmed in transgenic mice, KLF8 was specifically overexpressed in heart
tissue whereas in other tissue like fat; KLF8 overexpression was not observed (Fig.
31C). Phenotypic characteristics of these KLF8-hTg mice were studied alongside
different negative littermate control mice. The first noticeable difference identified was
higher mortality rate of cardiomyocyte specific KLF8 transgenic mice (Fig. 31D). As we
didn’t see any significant difference in mortality rate of the floxed, cre and WT control
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mice; those were clubbed together and compared against the mortality rate of positive
KLF8-hTg mice. Overall, successful construction of cardiomyocyte specific KLF8
transgenic mice showed similar early postnatal death as observed in global KLF8
transgenic mice suggesting the phenotype observed in KLF8-gTg mice might be caused
by KLF8 overexpression in cardiomyocytes.

KLF8-hTg mice phenocopy KLF8-gTg mice with systolic dysfunctional progression to
dilated cardiomyopathy:

As we already observed the similar trend in mortality rate in cardiomyocyte specific
KLF8 transgenic mice, we started investigating if the cause behind it corroborates with
the same of global transgenic mice. Necropsy demonstrated KLF8-hTg mice had larger
heart size compared to all the control littermate (Fig. 32A,C and Fig 33B). We used the
floxed control mice heart image as the representative negative control in this figure.
Furthermore KLF8-hTg mice hearts had significantly elevated level of myocardial
fibrosis (Fig. 32A,B and Fig 34) reasserting myocardial infarction in these mice. It was
finally validated by the increase of heart failure marker genes ANP and BNP in KLF8hTg mice hearts. Hemodynamic analysis interestingly unveils that the cardiomyocyte
specific KLF8 transgenic mice also have severe dilation of left ventricle (Fig. 32E) with
increased systolic and diastolic LV inner diameter and decreased ejection fraction,
fractional shortening; cumulatively pointing to dilated cardiomyopathy in these mice.
Time

point

echocardiograph

results

revealed

that

KLF8

overexpression

in

cardiomyocyte promotes systolic dysfunction at a very early age as we observed
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significant increase only in systolic LV diameter in transgenic mice from 1 month of age.
Eventually the KLF8-hTg mice LV became dilated as they aged with further severe
systolic dysfunction (Table 4 and Fig. 32F-I). To test if this novel KLF8 induced
phenotype is specific to its expression in cardiomyocyte, we constructed adipocyte
specific KLF8 transgenic mice by crossing FVB-B6-floxed-KLF8 (8th generation) with
C57BL/6J;FVB/NJ-Adipoq-Cre mice (Fig. 35A). Genomic DNA PCR and BLI validated
adipose specific KLF8 overexpression in the KLF8-aTg mice (Fig. 35B). However KLF8aTg mice didn’t show any change in mortality compared to different control groups
(Data not shown). Further hemodynamic analyses with these transgenic mice also didn’t
show any decline in left ventricular function (Fig. 35C). Additionally, KLF8-hTg mice had
significantly lower ejection faction compared to KLF8-aTg mice at the same 2 months of
age (Fig 35D) which strengthen our hypothesis that KLF8 overexpression specifically in
cardiomyocyte induces this novel cardiac phenotype. As we found the fat phenotype in
KLF8-gTg mice, we wanted to investigate if KLF8-hTg mice also have detrimental fat
accumulation effect. Interestingly, cardiomyocyte specific overexpression of KLF8 didn’t
demonstrate the decrease in mouse body weight, fat mass and adipocyte cell size,
taking food consumption into account (Fig 36A-D) which suggests that the fat
phenotype observed in global transgenic mice was probably not a direct consequence
of the cardiomyopathy. Some of the KLF8-hTg mice had lower body weight compared to
their respective littermate controls but overall it was not significant. Further studies with
KLF8-aTg mice will give us insight about the underlying mechanism of KLF8 induced
lipoatrophy.

81

Cardiovascular disease mRNA and miRNA PCR array to identify KLF8 regulated target
genes and miRNAs in context of Cardiomyopathy

As KLF8 is a known transcription factor, we hypothesized that KLF8 mediated
regulation

of

some

critical

genes

lead

to

systolic

dysfunction

and

dilated

cardiomyopathy. In view of increasing importance of micro RNAs in cardiomyopathy and
as KLF8 also has been shown to transcriptionally activate miR-146a and
transcriptionally repress miR-14, we decided to identify KLF8 regulated miRNAs in
parallel to mRNAs in dilated cardiomyopathy. Both mRNAs and miRNAs were isolated
from 3 pairs of KLF8-hTg mice heart left ventricles along with floxed littermate controls.
The most critical consideration was to select the mouse samples in an optimized age. In
order to negate out the dilated cardiomyopathy consequence gene signature, we
decided to use the mice with already decreased cardiac function (EF) but without
evident dilation of heart because change in heart size can significantly change the gene
expression signature. Cardiovascular disease mRNA and miRNA PCR array (Fig. 37)
was used to identify KLF8 regulated mRNA and miRNA targets respectively in KLF8hTg hearts from an array of 84 critical genes for various cardiomyocyte function. The
most significant regulated genes and micro RNAs with a P value less than 0.01 were
further validated by qPCR with specific primers. As KLF8 is a dual transcription factor,
we did find both upregulation and downregulation of some critical genes. The most
upregulated target of KLF8 includes Nppa, Col1a1, Col3a1, S100a8 and Stat1 whereas
downregulated genes include ATP2a2 and Anxa4 (Fig 38A-C). These gene target
regulation will be evaluated in early stage to onset of dilated cardiomyopathy in KLF8-
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hTg mice, which will identify the most probable KLF8 signaling axis as a cause of this
disease. We also did miRNA PCR array to identify possible micro RNA targets of KLF8
in the onset of cardiomyopathy. miR-122 was the most downregulated miRNA whereas
miR-208b was the most upregulated miRNA found in these transgenic mice heart (Fig
39A-C).
Potential KLF8 mediated upregulation of STAT1 in KLF8-hTg primary cardiomyocytes

To asses KLF8 mediated regulation of downstream targets; we isolated primary
cardiomyocytes from 5 days old KLF8-hTg mice and their floxed littermate controls (Fig
40). Our primary observation regarding these cells showed that KLF8-hTg mice
cardiomyocytes had slower contraction compared to floxed control (data not shown).
Further electrophysiological experiments will unveil this mystery from these cells. In
order to investigate KLF8 mediated target gene regulation in these cells, we first
explored STAT1 expression. Interestingly STAT1 was upregulated both at mRNA and
protein level in these cells along with KLF8 expression (Fig. 41A-B). We also found
increase in heart failure marker Nppa or ANP expression in KLF8-hTg mice
cardiomyocytes indicating possible onset of systolic dysfunction as earlier than 1 month
of age. To confirm KLF8 mediated STAT1 upregulation, we transiently transfected KLF8
in 293FT cells which showed significant upregulation of STAT1 mRNA expression (Fig.
41C). Further luciferase-promoter assay along with CHIP and BOP assay will be done
to investigate direct KLF8 mediated upregulation of STAT1 in the onset of this disease.
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Discussion

Comprehensively, this novel study with KLF8 transgenic mouse model revealed
a novel cardiac function of KLF8. KLF8 global transgenic mice had much higher mortal
rate compared to negative mice. The cause of death was evaluated as heart failure and
the transgenic mice had severe dilated hearts. Further cardiac hemodynamic analysis
characterized this disease as dilated cardiomyopathy with severe reduction in cardiac
output leading to death in transgenic mice. Time point hemodynamic analysis revealed
that KLF8 promotes systolic dysfunction as early as 4 weeks of age and that leads to
severe fatal dilated cardiomyopathy. As the first part of our study was performed in a
KLF8 transgenic mouse model where KLF8 is overexpressed in all tissues, we decided
to express it tissue specifically to explore more in depth role of KLF8 in cardiomyopathy.
Cardiomyocyte specific KLF8 overexpression led to the similar cardiac phenotype as
observed in global transgenic mice, unveiling KLF8 mediated gene regulation
specifically in cardiomyocytes induces this disease. In contrast we didn’t observe the
cardiac phenotype in adipocyte specific mice, thereby strengthening our hypothesis
about a novel KLF8 mediated signaling axis as potential cause of systolic dysfunction
and dilated cardiomyopathy.

Role of KLF8 in cardiac tissue has not been elucidated before in our knowledge
and this is the first report about a critical novel role of this cancer promoting gene.
Kruppel like family members have been implied before in cardiomyopathy, specifically
KLF4 [200], KLF11 and KLF15 [201, 202]. One study with KLF4 showed that KLF8
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expression

is

elevated

in

cardiomyocytes

of

angiotensin

induced

mouse

cardiomyopathy model which stands to reason after this study where we found KLF8
overexpression causes cardiomyopathy[203]. We also compared KLF8 mRNA
expression from NCBI GEO profile database, which clearly demonstrated higher
expression of KLF8 in patient samples with dilated cardiomyopathy. Both global and
cardiomyocyte specific mice showed the similar cardiac phenotype, which led us to
believe KLF8 expression in cardiomyocytes as the cause of cardiomyopathy. We
confirmed this notion when adipocyte specific mice didn’t show any cardiac phenotype.

In depth hemodynamic analysis of cardiac function from an early age of mice
demonstrated that KLF8 expression in cardiomyocytes leads to systolic dysfunction as
earliest which later on culminates into severe dilated cardiomyopathy. Systolic
dysfunction is abnormal pumping function in heart which initiates from contractile
dysfunction of cardiomyocytes [204, 205]. It has been well established that, reduction in
cardiomyocytes contractile potential deteriorates cardiac function. As heart cannot
pump enough blood throughout body which is characterized by decrease in ejection
fraction and fractional shortening, it goes through remodeling and tends to dilate to
contain more blood in the left ventricles which predominantly forms dilated
cardiomyopathy. Abrupt changes in gene signature are critical in cardiomyocyte
contraction. Innumerable studies have shown that mutation associated with the
cardiomyocyte sarcomere genes have direct relevance to pathogenesis of this disease
[121, 122, 206-208]. Cardiomyocyte contraction is a calcium dependent method, where
the myosin and actin bands slide against each other to initiate contraction using a
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mechanism unique to cardiac muscle called calcium-induced calcium release. After
receiving the stimuli, calcium influx in cardiomyocytes induces more calcium from
sarcoplasmic reticulum to cytoplasm. In a relaxed state, cardiac troponin binds to the
actin binding site of myosin and calcium binding to this protein removes it from that site
leading actin-myosin binding and initiation of contraction. Different studies with
transgenic, knockout models of these sarcomere genes proved them to be critical for
cardiac contraction and cardiomyopathy. In our mRNA PCR array we identified ATP2a2,
sarco/endoplasmic reticulum Ca2+-ATPase pump as a negatively regulated target of
KLF8. This calcium pump is critical in storing calcium ions in sarcoplasmic reticulum and
knock out model of this gene has been demonstrated to induce cardiomyopathy [209,
210]. In our model, KLF8 might transcriptionally repress ATP2a2 and therefore
promotes contractile dysfunction by depleting the calcium ions from cardiomyocytes.
We are currently identifying potential KLF8 regulated targets and cumulatively it will help
us to elucidate an overall KLF8 mediated gene regulation in cardiomyopathy.

One of the most significantly upregulated target found from mRNA array was
STAT1. Isolated primary cardiomyocytes from KLF8-hTg mice showed increase in
STAT1 expression at both mRNA and protein level. Further experiments are needed to
explore KLF8 mediated upregulation of STAT1. STAT1 has been elucidated in ischemia
induced cardiac injury. STAT1 has been found to be upregulated in ischemic
cardiomyopathy [211-213]. Later on it was found that STAT1 activate both intrinsic and
extrinsic cardiomyocyte apoptotic pathways by activating Caspase-1 and FADD
respectively [214, 215]. It was found that STAT1 knockout can protect mice from
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ischemic cardiac injury [211, 216]. Correlated with these findings, it has been also found
Caspase-1 transgenic mice develop heart failure [217, 218]. Overall cardiomyocyte loss
due to apoptosis has huge impact in cardiomyopathy [219-221]. We observed increased
apoptosis in KLF8-gTg mice heart (Fig 26) which helps us to form a hypothesis that
KLF8 mediated upregulation of STAT1 promotes to cardiomyocyte apoptosis further
leading to systolic dysfunction and dilated cardiomyopathy. Overall our proposed
schematic model (Fig 42) shows that KLF8 over expression in cardiomyocyte
upregulates and downregulates several critical mRNA and miRNA targets. Two of the
most potentially important target genes are STAT1 and ATP2a2. KLF8 mediated
upregulation of STAT1 can lead to cardiomyocyte apoptosis, further promoting systolic
dysfunction and dilated cardiomyopathy. KLF8 mediated downregulation of ATP2a2 can
potentially lead to decrease in cardiomyocyte contractility and systolic dysfunction

We also observed a novel fat phenotype in the global KLF8 transgenic mice.
KLF8-gTg mice had significantly less body weight and abdominal fat accumulation,
predominantly close to the reproductive organs. H&E staining revealed those KLF8-gTg
mice had significantly smaller adipocyte cell size. This novel fat phenotype was not
evident in cardiomyocyte specific KLF8 transgenic mice which led us to believe that
cardiac expression of KLF8 may not be responsible for this fat phenotype and it can be
induced by an independent KLF8 mediated regulation in a different tissue. We observed
the reverse phenotype in KLF8 global KO mice where fat mass was significantly
increased. In view of these result, we decided to construct adipocyte specific KLF8
transgenic mice to investigate if the fat phenotype observed is a consequence of KLF8
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expression in adipocytes. Both global and adipocyte specific KLF8 transgenic mice
demonstrated significant decrease in glucose tolerance which might be a key to this
unknown phenotype. Currently both these adipocyte specific transgenic and knock out
mice being studied to discover any novel function of KLF8 in adipose tissue.

Overall this study establishes the first KLF8 transgenic mouse model and
discovers a novel role of KLF8 in cardiomyopathy. In future, the signaling link of KLF8 to
onset of this cardiomyopathy will be explored. We currently are validating some KLF8
regulated critical mRNA and miRNA targets which will be studied for functional
significance in context of KLF8 in this transgenic mouse tissue and primary
cardiomyocytes obtained from these mice. KLF8 KO mice study in parallel will present a
great insight into the importance of KLF8 in cardiac tissue. Taken together this findings
not only discovers a novel unknown role of KLF8, it provides an outstanding tool to
study role of KLF8 in different diseases. Most available transgenic mouse models for
cardiomyopathy are induced by angiotensin and TAC surgery whereas our KLF8
cardiomyocyte specific transgenic mouse model presents a spontaneous dilated
cardiomyopathy disease model which can be of immense potential for drug testing and
therapeutic research in successful advancement of this cardiovascular field.

88

Figures

Figure 10. Validating KLF8 Transgene expression in vitro
(A) pTraffic-KLF8-Gl (KLF8 transgene) plasmid has been constructed to promote KLF8
overexpression. (B-D)The liberated linear transgene after digestion with Ssp1, Sfi1 were
transfected in 293 FT (human kidney cells) with lipofectamine 2000 (invitrogen). Cotransfection was also done with Cre (HA-Cre). The Cre vector used is pKH3-Cre which
expresses HA tagged Cre (42KD). Fluorescent microscopy (B) showed RFP to GFP
switch after Cre recombination. Western blot (C) with anti GFP (sc-9996; 1:1000), antiHA (SC-7392; 1:3000), anti-RFP (ab34771; 1:4000) and anti-beta-actin antibody (**;
1:4000) confirmed Cre recombination induce HA-KLF8 expression and RFP to GFP
switch. Luciferase assay result (D) also validated this result.
*, P<0.05; **, P<0.01; ***, P<0.001.
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Figure 11. Validation of Genotyping efficiency to detect low copy no of transgene
After validating in vitro, the transgene was sent to the University of Michigan transgenic
facility to construct the transgenic mice. To genotype the positive floxed-KLF8 mice, we
had to design a genotyping assay. (A-C) Genomic DNA PCR with two different primers.
WT is wildtype genomic DNA. Corresponding copy no of transgenic plasmids were
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mixed with WT genomic DNA in order to test the efficacy of this test. B-globulin
confirmed same amount of WT DNA. (D) Schematics of two sets of genotyping primers.
LoxP primers (red arrow) will detect amplification inside the loxP flanked sequence.
After loxP primer (blue arrow) will detect the transgene after the loxP sites. (E) These
primers and corresponding probes were used for taqman qPCR to standardize this
assay. (F) Standard curve based on different copy no of transgene detection gave a R 2
value of 0.97 which is very significant. We further used this standardized taqman qPCR
assay to detect the founder B65-Floxed-KLF8Tg mice.
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Figure 12. Genotyping to identify founder B65-floxed-KLF8 mice
(A-B) Taqman qPCR genotyping standardized assay was used to identify B65-floxedKLF8-Tg mice. Positive amplification indicated positive founder mice. (C) Genotyping
was also confirmed by genomic DNA PCR (pTg-K8 primer-1.4 kb amplification). Bglobin was used to confirm genomic DNA integrity.(D) As the floxed mice have RFP
expression, we also confirmed RFP expression from tail snips by fluorescence
microscopy (489 and 494 are positive and other two are negative). We also did RT-PCR
and western blot further to validate RFP expression (Data not shown).
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Figure 13. Schematic of transgenic mice breeding
B65-Floxed-KLF8Tg mice were backcrossed with FVB WT mice to get pure FVB strain
of mice. Currently we have backcrossed 11th generation FVB-floxed-KLF8Tg mice. We
also crossed B65-Floxed-KLF8Tg with FVB-EIIA-Cre mice to obtain global KLF8
transgenic mice (KLF8-gTg) which were observed for initial phenotypic changes due to
KLF8 overexpression globally.
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Figure 14. Construction of Global KLF8 Transgenic Mice
(A) Schematic model of Global KLF8 transgenic mice construction. After we identified
the B65-Floxed-KLF8 Tg mice; we crossed 4 separate founders with homozygous
FVB/N-TgN(EIIa-Cre)C5379Lmgd (Jackson lab stock 003314 ; This line carries a Cre
transgene under the control of the adenovirus EIIa promoter that targets expression of
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Cre recombinase to the early mouse embryo) mice. The offsprings were of mixed
FVB.B65 background including the Cre control and KLF8-gTg mice. (B-C)
Bioluminescence Imaging showed positive luciferase signal in KLF8-gTg compared to
control (B). Organ specific BLI (C) showed distribution of transgene expression in all
tissues. (D) KLF8-gTg mice have high expression of KLF8 mRNA compared to control
mice. QPCR was done for KLF8 mRNA expression (n=10) using universal KLF8 primer
(E) KLF8-gTg showed increased KLF8 and GFP protein expression. Western blot with
anti GFP (sc-9996; 1:1000), anti-KLF8 (8477; 1:1000), anti-RFP anti beta-actin antibody
(**; 1:4000) showed increased KLF8 expression in KLF8-gTg mice hearts.
*, P<0.05; **, P<0.01; ***, P<0.001.

Figure 15. Genotyping KLF8-gTg mice
KLF8-gTg mice were identified by genomic DNA PCR with two different primers on the
transgene. B-globin was used for genomic DNA integrity. We also did RT-PCR and
western blot with RFP, GFP and HA to validate the mice genotyping. As the EII-Cre
mice were homozygous and our floxed-KLF8 mice were heterozygous, the offspring
were wither KLF8-gTg or Cre control mice.
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Figure 16. KLF8 global transgenic mice showed increased heart size and
decreased survival rate.
(A-B) KLF8 global transgenic mice have significantly lower survival rate. KLF8-gTg mice
started dyeing from 4 months of age. We calculated the survival rate of both KLF8-gTg
mice (n=26) and control mice (n=23) and plotted in Kaplan-Meier survival plot (A) which
showed that KLF8-gTg mice has significantly lower survival rate. We also compared
survival rate of KLF8-gTg male (n=13) and female (n=13) which showed that the male
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mice had lower survival rate. (C-E) KLF8-gTg mice showed significantly increased heart
and lung size. KLF8-gTg mice heart was collected along with its littermate control mice.
Both heart and lung were washed in PBS and imaged longitudinally. KLF8-gTg mice
showed increased heart and lung size compared to negative control (C). Both heart
weight (D) and lung weight (E) were significantly increased in KLF8-gTg mice (n=12).
This increase in heart and lung was observed in both male and female mice. (F) KLF8gTg mice showed less body weight. Both KLF8-gTg and control mice were weighed
before euthanasia and KLF8-gTg mice body weight was significantly less compared to
control mice (n=12). (g) KLF8-gTg mice heart has positive HA-KLF8 expression. These
heart sections were used for IHC staining with anti-HA (Sc-7392; 1:200) antibody.
*, P<0.05; **, P<0.01; ***, P<0.001.

Figure 17. KLF8-gTg mice heart samples
KLF8-gTg mice showed enlarged heart compared to negative Cre control mice. These
mice are of different ages (Ranging from 5 months to 15 months). All the KLF8-gTg
mice hearts are aligned with its control littermate Cre control mice hearts.
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Figure 18. KLF8-gTg mice shows a lean characteristic in BLI
Bioluminescence Imaging revealed a lean phenotype in the KLF8-gTg mice compared
to its littermate Cre control mice.
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Figure 19. Investigating KLF8-gTg mouse different tissues for any phenotypic
characteristics
Various tissues of KLF8-gTg mice were compared with its littermate negative control
mice tissues for any evident phenotypes. We also did H&E staining to investigate any
microscopic differences in tissue morphology. We didn’t see any evident phenotypes or
morphological differences in KLF8-gTg mice Brain (A), Liver (C), Lung (D), Muscle (E),
Spleen (F), Intestine/stomach (G), Kidney (H). KLF8-gTg mice abdominal fat (B) and
reproductive fat (I) was less compared to the negative control.
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Figure 20. KLF8 global transgenic mice showed less accumulation of Fat.
(A-C) KLF8-gTg mice showed decreased body weight compared to control. KLF8-gTg
mice had very little abdominal (A) and reproductive (C) fat (indicated by black arrow)
compared to littermate control. KLF8 transgenic mice almost had 70-80% decreased fat
amount compared to negative control mice (B; n=12). (D) H&E staining of Fat sections
showed that KLF8 transgenic mice reproductive fat had much decreased adipocyte cell
size compared to control mice. (E) 4 months old transgenic and control mice (n=2) were
housed in individual cages with same amount of food. We measured the food intake
each 4 days (Food shredded by mice were also taken into consideration). After 24 day
experiment the food intake was plotted against time and the food consumption plot
didn’t show much difference between KLF8-gTg and control mice.
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Figure 21. KLF8-gTg mice showed decrease in both brown and white adipose
tissue.
(A) We observed significant decreased brown adipose tissue (back of neck) mass and
(B) white adipose tissue (both abdominal and reproductive) mass in KLF8-gTg mice
compared to Cre control littermates.
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Figure 22. Global expression of KLF8 induces dilated cardiomyopathy in
transgenic mice
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(A-B) KLF8-gTg mice showed increased myocardial fibrosis (light blue color; indicated
by black arrow heads) (A). Cardiac fibrotic area (light blue) was analyzed with image J
software (n=8) and plotted (B). Quantification showed that KLF8-gTg showed
significantly increased interstitial fibrosis. (C-E) KLF8-gTg mice heart had increased
expression of heart failure markers. KLF8-gTg and control mice hearts RNA were
collected and used for qPCR with mouse beta-MHC (C), ANP (D) and BNP (E) primers
(n=8). All these heart failure markers showed increased expression in transgenic heart
compared to control heart RNA. (F-J) Hemodynamic analysis showed KLF8 induces
dilated cardiomyopathy in transgenic mice. Ultrasound echocardiograph was done with
KLF8-gTg and control mice (n=20 each group) to measure cardiac function. All M mode
pictures were measured with ultrasonic software and tabulated. Table 1 showed that
both KLF8-gTg male and females showed significant increased LVIDd (G), LVIDs (H)
and decreased EF (I) and FS (J) whereas there was no significant change in ventricular
wall and intraventricular septum.
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Figure 23. Trichrome staining of KLF8-gTg mouse hearts along with littermate
controls
Masson’s trichrome staining of 5 pairs of mixed background KLF8-gTg mice hearts
along with negative littermate control. All of them showed increased myocardial fibrosis
in KLF8-gTg mice hearts.
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Control

KLF8-gTg

Figure 24. Severe deterioration in progressive cardiomyopathy in KLF8-gTg mice
One pair of KLF8-gTg mouse and its control negative littermate hemodynamics are
shown above to indicate the severity of this cardiomyopathy. The top data table is of 14
months while the bottom one is of 11 months of age. The Ejection fraction (EF) of KLF8gTg deteriorates from 50% to 10% in these 3 months while the negative littermate didn’t
show any change. Corresponding systolic LV diameter increased severely in KLF8-gTg
mice in 3 months and its heart became further dilated which is indicated by increase in
diastolic LV diameter. The images shown above are of 14 months of age which clearly
showed that KLF8-gTg mice had severely impaired systole.
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Table 2. Hemodynamic analysis Lahiri.
of KLF8
transgenic
mice cardiac function
1.
al. Table
et.global

Hemodynamic analysis was done with 10 month old mice. Numbers are mean6SEM. LV, left
ventricle; IVSd, intraventricular septum diastolic; LVIDd, left ventricle inner diameter diastolic;
LVPWd, left ventricle posterior wall diastolic; %EF, percentage of ejection fraction, %FS,
Fractional shortening.
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Figure 25. Hemodynamic analysis of adult KLF8 global transgenic mice cardiac
function
Both adult male and female KLF8-gTg mice showed significant increase in LV diameter
in diastole (A), LV diameter in systole (B), LV volume in diastole (C) and LV volume in
systole (D). These parameters were further increased after 4 months in KLF8-gTg mice
whereas both negative control (Cre control and floxed control) didn’t show much
difference. Further KLF8-gTg mice also showed significantly decreased ejection fraction
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(EF) and fractional shortening (FS) compared to negative controls. Both EF and FS was
severely deteriorated in KLF8-gTg mice while we didn’t observe much change in the
controls.

Control

KLF8-gTg

Figure 26. KLF8-gTg mice showed more apoptosis in heart
Tunnel staining was done with mouse heart tissue samples. KLF8-gTg mice heart
clearly showed much more apoptosis (green) compared to the negative control mice
heart. Red channel was used to negate the auto fluorescence. Tunel assay was done
with Deadend Flurometric Tunel system (Promega G3250)
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Figure 27. Higher expression of KLF8 transgene correlates with the severity of
cardiac dysfunction
(A-D) KLF8 high expression mice showed significantly increased LV diameter at both
systole and diastole and decreased EF and FS. We grouped the mice based on
transgene expression (BLI data not shown).
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Table 3.Hemodynamic analysis based on KLF8 transgene expression

Numbers are mean6SEM. LV, left ventricle; IVSd, intraventricular septum diastolic; LVIDd, left
ventricle inner diameter diastolic; LVPWd, left ventricle posterior wall diastolic; %EF, percentage
of ejection fraction, %FS, Fractional shortening.
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Figure 28.
KLF8 induces systolic dysfunction which leads to dilated
cardiomyopathy in KLF8 global transgenic mice.
Time point hemodynamic analysis showed that heart size in transgenic mice increases
from 3 months of age (A). (We use FVB-K8-gTg mice which had lower survival rate
compared to the mixed control). (B-E) shows that KLF8 promote increase in LV systolic
diameter which leads to decrease in EF, FS at 1 month of age. Time point analysis
showed further deterioration of cardiac function in transgenic mice which leads to
dilated cardiomyopathy.
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FVB background
Mixed (B65 X FVB) background
Figure 29. Survival rate of Different strain background of KLF8-gTg mice
Both FVB and mixed background KLF8-gTg had lower survival rate compared to their
respective negative controls.

114

A

B

Figure 30. Cardiac phenotype is observed independent of mouse strain
background
Overall our study we used two different strains of KLF8-gTg mice. Both FVB
background mice (A) and mixed background KLF8-gTg mice (B) showed lean
phenotype, enlarged heart and less fat phenotypes.
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Figure 31. Construction
of cardiomyocyte specific KLF8 transgenic mice

(A) Construction of cardiomyocyte specific KLF8 transgenic mice (KLF8-hTg): FVB-B6th
floxed-KLF8 (7 generation) mice were crossed with B6-FVB-Tg-Myh6-Cre mice. We
got 4 different off springs including KLF8-hTg, floxed control, Cre control and WT control
mice. (B) KLF8-hTg mice showed heart specific transgene expression: We did BLI with
KLF8-hTg mice along with the littermate controls and the KLF8-hTg mice showed heart
specific luciferase expression. The control littermates did not show any luminescence.
(C) Confirm KLF8 mRNA overexpression specific to heart tissue of KLF8-hTg mice
compared to fat tissue of these mice. RNA from both KLF8-hTg mice heart and fat were
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isolated along with floxed control mice. qPCR was done using universal KLF8 primer
(detects both human and mouse KLF8) to investigate KLF8 expression in these tissues.
(D) Survival rate of KLF8-hTg mice is much lower compared to control mice (none of the
3 control group mice died as early as the KLF8-hTg mice, so we pooled all the control
mice in a single negative control mice group and plotted against KLF8-hTg mice.
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Figure 32. Cardiomyocyte specific over-expression of KLF8 induces systolic
dysfunction leading to dilated cardiomyopathy
(A-B) KLF8-hTg mice showed increased heart size and cardiac fibrosis. Heart size (A)
and weight (C) was significantly higher in KLF8-hTg compared to all three control. We
used floxed control mice here as representative figure. We used these heart sections to
do mason’s trichrome staining to check collagen deposition in cardiac tissue (light blue
color; indicated by black arrow heads). KLF8-hTg mice showed positive cardiac fibrosis
compared to control mice heart (A). Cardiac fibrotic area (light blue) was analyzed with
image J software (n=6) and plotted (B). Increase in heart failure markers ANP and BNP
were also observed in KLF8-hTg mice hearts (D). KLF8-hTg mice along with its control
littermates were used for ultrasound to investigate heart function. Ultrasound result
showed cardiac expression of KLF8 leads to increased LVIDs and decreased EF, FS in
KLF8-hTg mice. (E-I) Cardiomyocyte specific expression of KLF8 also induce systolic
dysfunction: Time point haemodynamic analysis of KLF8-hTg along with its control
littermates showed that KLF8-hTg mice hearts have increased LVIDs and decreased
EF,FS. Heart function in KLF8-hTg mice deteriorates faster compared to negative
controls. We have not yet seen significant change in heart LVIDd but these mice are
still studied each month to investigate if this systolic dysfunction leads to dilated
cardiomyopathy. We use FVB-K8-gTg mice which had lower survival rate compared to
the mixed control). (F-I) shows that KLF8 promote increase in LV systolic diameter
which leads to decrease in EF, FS at 1 month of age. Time point analysis showed
further deterioration of cardiac function in transgenic mice which leads to dilated
cardiomyopathy.
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Figure 33. Cardiomyocyte specific KLF8 transgenic mice heart samples
(A) Cardiomyocyte specific KLF8 transgenic mice (KLF8-hTg) didn’t show very clear
lean phenotype in BLI. (B) KLF8-hTg mice had enlarged heart compared to their
negative controls (Negative controls include floxed control, cre control and WT control).
The hearts on the top row were collected before heart became dilated for PCR array
study.
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et. al. Tablespecific
Lahiri.
Table 4. Hemodynamic analysis of
Cardiomyocyte
KLF8 transgenic mice

Hemodynamic analysis was done from 1 month old mice. This table demonstrated 3 months old
mice data. Numbers are mean6SEM. LV, left ventricle; IVSd, intraventricular septum diastolic;
LVIDd, left ventricle inner diameter diastolic; LVPWd, left ventricle posterior wall diastolic; %EF,
percentage of ejection fraction, %FS, Fractional shortening.
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Figure 34. KLF8-hTg mice hearts showed much increased myocardial fibrosis
Representative images of KLF8-hTg mice hearts’ masson’s trichrome staining revealed
significantly higher myocardial fibrosis (primarily in the ventricular area) in positive mice
compared to negative controls (Light blue color indicates fibrosis).
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Figure 35. Cardiomyocyte specific KLF8 transgenic mice didn’t show significant
difference in the fat phenotype.
(A-B) KLF8-hTg mice didn’t show significant decrease in fat volume and adipocyte cell size. (CD) We performed food consumption test with these mice (n=3) and the results demonstrated no
significant change in food uptake which would have excluded food consumption difference as a
cause for any fat phenotype observed.
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Figure 36. Adipocyte specific KLF8 overexpression didn’t show cardiomyopathy
(A) Construction of adipocyte specific KLF8 transgenic mice (KLF8-hTg): FVB-B6-floxed-KLF8
th
(8 generation) mice were crossed with C57BL/6J;FVB/NJ-Adipoq-Cre mice. We got 4 different
offsprings including KLF8-hTg, floxed control, Cre control and WT control mice. (B) BLI
identified abdominal fat specific luminescence in the KLF8-aTg mice compared to the negative
control. (C) Ultrasound with KLF8-aTg mice along with its control didn’t show any significant
change in cardiac function in transgenic mice. (D) We compared cardiac function of 2 months
old KLF8-aTg and KLF8-hTg mice which revealed significant cardiac dysfunction in KLF8-hTg
mice.
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Figure 37. Schematic diagram of cardiovascular mRNA and miRNA PCR array
(SABioscience)
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Figure 38. Cardiovascular disease mRNA PCR array
(A) Heat map of cardiovascular disease mRNA PCR array (N=3). qPCR to validate KLF8
upregulated (B) and downregulated (C) mRNA targets in cardiomyopathy.
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Figure 39. Cardiovascular disease miRNA PCR array
(A) Heat map of cardiovascular disease miRNA PCR array (N=3). qPCR to validate KLF8
upregulated (B) and downregulated (C) miRNA targets in cardiomyopathy.
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Figure 40. Isolation of primary cardiomyocytes
Primary cardiomyocyte was isolated and cultured from 5 days old KLF8-hTg mice and
their littermate controls using Pierce™ Primary Cardiomyocyte Isolation Kit.
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Figure 41. STAT1 upregulation in isolated primary cardiomyocytes from KLF8hTg mice
(A) Validating mRNA fold increase in KLF8, ANP and STAT1 in KLF8-hTg
cardiomyocytes compared to floxed control. (B) Western blot showed increase in both
KLF8 and STAT1 expression in KLF8-hTg mouse cardiomyocytes. (C) KLF8 transient
transfection in 293FT cells further induced increase in STAT1 expression suggesting
KLF8 mediated upregulation of STAT1.
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Figure 42. Proposed schematic model of KLF8 mediated dilated cardiomyopathy
KLF8 over expression in cardiomyocyte upregulates and downregulates several critical
mRNA and miRNA targets. Two of the most potentially important target gene are
STAT1 and ATP2a2. KLF8 mediated upregulation of STAT1 can lead to cardiomyocyte
apoptosis, further promoting systolic dysfunction and dilated cardiomyopathy. KLF8
mediated downregulation of ATP2a2 can potentially lead to decrease in cardiomyocyte
contractility and systolic dysfunction.
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CHAPTER 4: CONCLUSION

Overall my work addresses two novel characteristic of KLF8. KLF8, a dual
transcription factor have been implicated in promoting different cancer progressions.
Both independent studies in parallel provide unexplored KLF8 behavior and function.
One of these studies identifies a novel post-translational modification of KLF8 in context
of cancer while the other discovers a novel unknown function in KLF8 in
cardiomyopathy, thereby implying the increasing physiological importance of this
protein. We constructed the first KLF8 transgenic model which is not only essential for
this current study but also provides an outstanding tool in both KLF8 and cardiovascular
research field.

Various post-translational modifications including sumoylation, acetylation,
parylation have been found to regulate KLF8 function, localization and expression. We
discovered a novel phosphorylation of KLF8 at serine 48 to add in the KLF8 posttranslational modification paradigm. ERK2 was identified as the responsible kinase in
phosphorylating KLF8 at this novel site. Further studies revealed that ERK2
phosphorylation of KLF8 is critical for its protein stability and involvement in cancer cell
migration. In absence of Serine 48 phosphorylation, KLF8 had much shorter half-life
and potential for promoting cancer cell migration in vitro. Taken together, this study not
only discovers the novel site on KLF8 but also links ERK2 to KLF8 in order to establish
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as a downstream effector of MAP kinase pathway. Inter regulatory role between
different post-translational modification of a same protein has found to be critical for
their physiological function. In view of KLF8, sumoylation and acetylation act against
each other to regulate transcriptional regulator function of KLF8. In one of the KLF8
mutants (d31-35) with hyper phosphorylation state, we observed an evident change in
KLF8 sumoylation pattern which suggests that this novel phosphorylation site of KLF8
might be critical for the other post-translational modification. This study also provides
critical future directions by revealing few novel sites of KLF8 like P37, P38, E39, I40
mutants which affect KLF8 motility and expression pattern. We also discovered two
interesting motifs on KLF8 N terminal 31-35 and 36-40 region, which have
intraregulatory role on phosphorylation at Serine 48. While the first motif negatively
regulates S48 phosphorylation, the second one activates it which suggests potential
protein phosphatase binding to KLF8 to the first motif and ERK2 binds to the second
motif. Investigating the mechanism of these motifs can potentially discover novel
interacting partners, structure, functions of KLF8 advancing our understanding on KLF8
further. Finally this study suggests a novel nuclear degradation mechanism of KLF8
which is more relevant as KLF8 localization in nucleus is critical for its function. Posttranslational modifications have been implicated to regulate a protein function by
various studies. KLF8 S48 phosphorylation was also proved to be essential in KLF8
mediated cancer cell migration. Taken together, we identified a novel phosphorylation
site of KLF8 critical for its stability, ERK2 as the upstream kinase and a novel ERK2KLF8 signaling axis linking to KLF8 mediated breast cancer cell migration providing a
great potential for future research on KLF8 as an oncogene.
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KLF8 involvement in cancer has been studied in vitro and xenograft model so far.
To investigate role of KLF8 in a better physiologically relevant context, we constructed
the first novel KLF8 transgenic mice. As mentioned before, being equipped with Creloxp, these transgenic mice provide great potential to study tissue specific function of
KLF8. We also constructed a KLF8 KO mouse model which is not elucidated in this
study. Our KLF8 transgenic mice with KLF8 expression globally started dying much
earlier compared to control mice and later on dilated cardiomyopathy was identified as
the potential cause of this higher mortality. Cardiomyocyte specific KLF8 transgenic
mice unveiled that the systolic dysfunction and dilated cardiomyopathy phenotype is an
effect of KLF8 overexpression in cardiomyocytes. No studies to our knowledge, have
demonstrated any involvement of KLF8 in cardiac tissue till date which makes these
finding extremely novel and exciting. This further implies the significance of exploring a
protein’s function in genetically engineered mouse model.

Diverse studies demonstrated that Kruppel like factors shared some critical
function. Since discovering this novel function of KLF8 in cardiomyopathy in KLF8
transgenic mouse model, we wanted to review the literature to evaluate transgenic or
knock out mouse models of other KLF members to investigate the involvement of this
family genes in cardiomyopathy. Krüppel-like Factor 2 (KLF2), also known as lung
Krüppel-like Factor (LKLF) is involved in lung development, T-Cell viability and
adipogenesis.KLF2 ko mice were embryonic lethal and died at embryonic 12.5 to 14.5
days due to severe intra-embryonic and intra-amniotic hemorrhaging[222]. It was found
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that KLF2 is an important factor for blood vessel formation as lack of KLF2 led to thin
blood vessel wall and thin arteries. Vascular smooth muscle cells in the aortae from the
LKLF-/- animals displayed a cuboidal morphology and failed to organize into a compact
tunica media [223]. As KLF2-/- mice were embryonic lethal, not much post-natal
application of these mice are available. Cell specific knock out of KLF2 showed delayed
lung development, defective T cells and defective adipocyte differentiation [224-227].
Myeloid

cell

specific

KLF2

inactivation

increases

Atherosclerosis

in

hypercholesterolemic mice[228, 229]. KLF3 originally termed Basic Krüppel-like Factor
(BKLF) acts mainly as a transcriptional repressor. KlF3 knockout mice have less white
adipose tissue, and their fat pads contain smaller and fewer cells[230]. Overexpression
of Klf3 inhibits adipocytic differentiation of 3T3-L1 cells in vitro[230]. Krüppel-like Factor
4 (KLF4), also known as gut enriched Krüppel-like Factor (GKLF) is a tumor suppressor
in colon cancer. It also plays important role in regulating adipogenesis. KLF4 has been
proved to be a critical factor in inducing pluoripotent stem cells along with other known
factors like Sox2, nanog[231]. In vitro studies have suggested that Klf4 plays an
important role in skin cell proliferation and/or differentiation [232]. Mice homozygous for
a null mutation in Klf4 die within 15 hours of birth and show selective perturbation of
late-stage differentiation structures in the epidermis. Klf4–/– mice possessed a defective
epidermal barrier which was the cause of death [233]. Klf4−/− mice also show abnormal
differentiation of goblet cells but not colonocytes or enteroendocrine cells in the colon.
These mice also showed altered expression of goblet cell marker Muc2 [234].
Expression of Kruppel-like factor KLF4 in mouse hair follicle stem cells contributes to
cutaneous wound healing[235]. Induction of KLF4 in basal keratinocytes blocks the
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proliferation−differentiation switch and initiates squamous epithelial dysplasia [232].
Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. By in vivo
EC-specific KLF4 overexpression it was found that KLF4 induced an antiadhesive,
antithrombotic state [236]. Krüppel-like Factor 5 (KLF5), also known as intestinal
enriched Krüppel-like Factor (IKLF) is involved in intestinal homeostasis, cardiac
remodeling, lung maturation, adipogenesis. It has been also shown to be involved in
breast and prostate cancer. KLF5 knockout mouse was embryonic lethal at E8.5 days
[237]. Heterozygous and tissue specific knock out of KLF5 showed reduced cardiac
fibrosis and hypertrophy in response to stress [238]. It also showed deficiencies in white
adipose tissue formation, defective lung morphogenesis [239, 240]. Other studies
showed that the TIEG−/− knock-out mouse developed features of cardiac hypertrophy
including asymmetric septal hypertrophy, an increase in ventricular size at age 16
months, an increase (214%) in mouse heart/weight body weight ratio TIEG−/−, and an
increase in wall thickness in TIEG−/− mice of (1.85 ± 0.21 mm), compared to the control
(1.13 ± 0.15 mm, P < 0.04). Masson Trichrome staining demonstrated evidence of
myocyte disarray and myofibroblast fibrosis[241]. KLF10-/- mice showed increased skin
tumor formation and acts as a tumor suppressor[242]. KLF11 also known as TIEG2
(transforming growth factor β (TGF-β)-inducible gene) plays important role in cardiac
hypertrophy. It also plays tumor suppressor role in pancreatic cancer. Cardiac-specific
KLF11 transgenic mice do not show any difference from their littermates at baseline.
However, cardiac-specific KLF11 overexpression protects mice from TAC-induced
cardiac hypertrophy[243]. KLF11 knockout mice showed normal development and life
span. One recent study showed that KLF11 knockout mice (Klf11−/−) showed
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decreased Mono Amine Oxidase A (MAO A) mRNA expression and catalytic activity,
which supports the substantial role of KLF11 in the up-regulation of MAO A[244].
Interestingly, the differences in MAO A expression were readily amplified after
dexamethasone exposure. KLF13 is involved in cardiac development, T-cell and B-cell
development. Krüppel-like factor 15 also known as KKLF (kidney-enriched Krüppel-like
factor) is a regulator of cardiac hypertrophy. It also plays important role in
gluconeogenesis. Overexpression of KLF15 transcription factor in adipocytes of mice
results in down-regulation of SCD1 protein expression in adipocytes and consequent
enhancement of glucose-induced insulin secretion [245]. KLF15/A mice are transgenic
mice specifically overexpressing transcription factor KLF15 (Kruppel-like factor 15) in
skeletal muscle. This strain expresses full-length cDNA encoding mouse KLF15 under
the control of human α actin promoter. This strain doesn’t show specific phenotype, but
it’s suggested that KLF15 may increase GLUT4 expression level [246, 247]. KLF15-null
mice are viable but, in response to pressure overload, develop an eccentric form of
cardiac hypertrophy characterized by increased heart weight, exaggerated expression
of hypertrophic genes, left ventricular cavity dilatation with increased myocyte size, and
reduced left ventricular systolic function[248]. KLF15-/- liver and skeletal muscle show
markedly reduced mRNA expression of amino acid-degrading enzymes. Furthermore,
the enzymatic activity of alanine aminotransferase (ALT), which converts the critical
gluconeogenic amino acid alanine into pyruvate, is decreased in KLF15-/- hepatocytes.
This leads to hypoglycemia in KLF15-/- mice [249, 250]. One recent study showed that
KLF15 plays an important role in cardiac lipid metabolism[251].
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We are currently investigating KLF8 regulated mRNA and miRNA targets in the
onset of dilated cardiomyopathy in transgenic mice. We are also characterizing
adipocyte specific KLF8 transgenic mice to evaluate KLF8 mediated decrease in white
adipose tissue accumulation. In addition, we constructed KLF8 mammary specific
transgenic mouse by crossing FVB-floxed-KLF8 with FVB-MMTV-Cre mouse. These
mice are being observed for mammary tumorigenesis to asses KLF8 role in breast
cancer in vivo. KLF8 KO mice model for these different tissues are also maintained
providing an ideal platform to evaluate critical role of KLF8 in diverse diseases.
Currently identified mRNA targets of KLF8 from KLF8-hTg hearts include Nppa, Stat1,
S100a8, Col1a1, Col3a1, ATP2a2 and Anxa4. Some of these targets might be indirectly
regulated by KLF8. Nppa or natriuretic peptide A is a heart muscle secreted hormone
which is responsible for controlling blood pressure by clearing fat and other metabolites
from circulation. Nppa or ANP is a known biomarker for cardiovascular diseases and it
is upregulated during heart failure [252, 253]. Nppa upregulation in KLF8-hTg mice can
be the response of systolic dysfunction but we will validate if there is any direct KLF8
mediated regulation of Nppa in these mice which might contribute to the cardiac
phenotype. Signal transducers and activators of transcription (STAT1) is one of the
other important upregulated targets in these mice hearts. STAT1 has been found to be
overexpressed in cardiomyocytes during ischemic injury [214, 215]. These studies
further demonstrated that STAT1 activates pro-apoptotic factor caspase 1 to promote
cardiomyocyte apoptosis. We also observed increased cardiomyocyte apoptosis in
KLF8-gTg hearts. KLF8 might activate this apoptotic pathway through caspase 1 by
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upregulating STAT1 expression in cardiomyocytes. STAT1 inhibitors have been used to
prevent cardiac hypertrophy [212, 216]. STAT-1 has been also found to be involved in
mediating myocardial fibrosis [254, 255]. Col1a1 and Col3a1 genes are critical for
collagen synthesis during cardiac remodeling and fibrosis [256]. S100 calcium-binding
protein A8 (S100A8) is a protein, also known as calgranulin A is a calcium binding
protein. There has not been much research about this protein in dilated
cardiomyopathy. Although one study recently showed that S100a8 exasperate postischemic heart failure by activating both MAP kinase and NF-kB pathway [257]. KLF8
has been previously identified to activate EGFR/ERK and NF-kB signaling pathway.
This link through KLF8 mediated upregulation of S100a8 might prove critical for
cardiomyopathy. KLF8-hTg mice heart mRNA PCR array found ATP2a2 and Anxa4 as
the downregulated targets. ATP2a2 or Serc2a2 has been discussed before in chapter 3
discussions. Anxa4 or Annexin 4A is a calcium dependent phospholipid binding protein.
It is critical for cardiomyocyte contraction. One study showed that Annexin 4 is
upregulated in failing heart [258]. We have to investigate further to interpret this result.

KLF8-gTg mice showed a very prominent fat phenotype other than the
predominant cardiac phenotype. KLF8-gTg mice had significantly less epididymis and
reproductive white adipose fat compared to littermate control. White adipose tissue cells
were much smaller in size in KLF8-gTg mice. We didn’t observe this phenotype in
KLF8-hTg mice as evident as KLF8-gTg. This result suggested a different KLF8
mediated signaling cascade regulating this fat phenotype. Our hypothesis was further
strengthened when we observed KLf8-Ko mice showing excessively increased white fat
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compared to their littermate controls (data not shown). We started constructing
adipocyte specific KLf8 transgenic mice (KLF8-aTg) to decipher this mystery. This part
of research is still in progress. We didn’t observe body weight change in these mice yet.
We sacrificed one pair of KLF8-aTg mice of 4 months of age. After necropsy, we
observed little reduction in primarily brown adipose tissue (Fig 43). H&E staining didn’t
show much difference in white and brown adipose tissue morphology between KLF8aTg and its littermate floxed control mice (Fig 44). To unveil the metabolism of KLF8gTg mice, we performed glucose and insulin tolerance test with KLF8-gTg mice.
Interestingly, our preliminary results showed significant increase in glucose and insulin
tolerance in KLF8-gTg mice compared to its littermate controls (Fig 45 A-B) further
linking to the reduced fat phenotype. We also performed these experiments with KLF8hTg mice to investigate if cardiomyocyte expression of KLF8 has any role to play in
metabolism although we didn’t see any evident phenotype. Surprisingly, we observed a
similar increased glucose and insulin tolerance trend in KLF8-hTg mice (Fig 45 C-D)
which further suggests that KLF8 expression in cardiomyocytes might have a partial role
to play in this fat phenotype and there might be a novel systemic role of KLF8 in
initiating both these cardiac and fat phenotypes. Excitingly KLF8 global KO had
decreased glucose tolerance and increased insulin resistance which is a potential
prediabetes condition (data not shown). Overall it also proposes that KLF8 might have a
protective role in diabetes and KLF8-gTg mice might develop obesity and diabetes later
than control mice in a high fat diet induced experiment. Further investigation in this
regard have immense potential of discovering a novel unknown role of KLF8 in
adipogenesis.
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Our primary aim was to study tumorigenesis in KLF8 transgenic mice as KLF8
function has been mostly researched in different cancers. Our KLF8-gTg mice were
dying much earlier because of dilated cardiomyopathy and possibly masked any
possible tumorigenesis as spontaneous tumorigenesis takes a long time to develop.
Excitingly two pairs of KLF8-gTg mice which were alive till 8 months of age
demonstrated tumor like structure. One of the KLF8-gTg mice developed testicular
tumor and other one developed mammary hyperplasia. Both of these tumor-like tissues
were positive for ki-67 staining. To study tumorigenesis mediated by KLF8 in a greater
extent, we developed first mammary specific KLF8 transgenic mice by crossing FVBfloxed-KLF8 and FVB-MMTV-Cre mice. Currently these mice are kept under
observation for any potential mammary tumorigenesis. As KLF8 role in cancer has been
elucidated in different tissues, our floxed KLF8 mice can be crossed with various tissue
specific Cre mice to identify KLF8 role in multiple cancer and other unknown diseases.

Finally, this work has extended the knowledge on KLF8 in cancer and
cardiovascular research to great measures. Identification of ERK2 mediated KLF8
phosphorylation proposed a new feedback loop including KLF8/EGFR/ERK2/KLF8-p
which might be critical for KLF8 mediated tumorigenesis and metastasis. Further, this
project identifies various critical amino acids for KLF8 structure which later can reveal
novel regulation of KLf8. We established the first KLF8 transgenic and knock out mouse
model in a Cre-loxP induced system which will be a great asset to dissecting KLF8
function in different diseases. Our work on KLF8 in cardiomyopathy is the first literature
on KLF8 involvement in heart failure and future research exploring the underlying
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mechanism will give rise to novel KLF8 mediated signaling cascades in onset of fatal
dilated cardiomyopathy. Future goal will be to inhibit KLF8 with small molecule inhibitors
in order to prevent progression of this disease. Overall, this work will establish KLF8 as
a novel therapeutic target of both cardiomyopathy and cancer, two most deadly
diseases in our time.
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Figures
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Floxed

KLF8-aTg

Figure 43. KLF8-aTg mice necropsy
KLF8-aTg mice of 4 months of age were sacrificed along with floxed control mice. We
didn’t observed significant change in white adipose tissue (both abdominal and
reproductive fat). We observed a slight decrease in brown fat volume. These mice are
currently under observation for any phenotypic change.
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Figure 44. H&E staining of KLF8-aTg mice adipose tissues
We didn’t observe any change in KLF8-aTg mice white adipocyte and brown adipocyte
cell size and no compared to floxed mice.
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Figure 45. KLF8-gTg and KLF8-hTg mice glucose and insulin tolerance test
(A-B) KLF8-gTg mice glucose tolerance (A) and insulin tolerance (A) showed that KLF8gTg mice have increased glucose tolerance and insulin sensitivity. (C-D) KLF8-hTg
mice glucose tolerance (C) and insulin tolerance (D) showed similar trend but was not
significant.
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Figure 46. KLF8-gTg mice developed testicular tumor

(A-B) KLF8-gTg mice developed testicular tumor which was positive for BLI signal. (CD) Tumor was found to be attached with ductus deferens. (E) H&E staining shows
neoplasia in the potential tumor tissue.
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Figure 47. KLF8-gTg mouse testicular tumor was positive for ki-67 staining
We confirmed HA-KLF8 expression in KLF8-gTg mice testicular tumor tissue. Most of
the cells in this tumor-like tissue were highly proliferative which was confirmed by
positive ki-67 staining (Right panel).
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Figure 48. KLF8-gTg mice developed testicular tumor
(A-B) FVB background KLF8-gTg mice developed mammary tumor which was positive
for BLI signal. (C) Tumor was found to be attached with mammary fat pad. (D) H&E
staining shows neoplasia in the potential tumor tissue.
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Figure 49. KLF8-gTg mouse showed mammary hyperplasia
We confirmed accumulation of cells by increase in nuclear staining by H&E. Most of the
cells in this tumor-like tissue were highly proliferative which was confirmed by positive
ki-67 staining (Right panel).
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Figure 50. Future Prospective
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Floxed-KLF8 mice genotyping:

•

23 positive mice were received in the transgenic mice facility and left in
quarantine for 5 weeks. 478 (0730) mouse was found dead in the transgenic
facility, so we are left with 22 mice. After they are declared clean, 1-2 cm of tail
from each mouse was snapped.

•

Before cutting tail, we tried bio-fluorescent imaging at the vivarium to see the
expression of RFP and GFP, but due to high background it was not clearly
identified. Nude mice were used as a negative control. The tails were observed
for RFP expression under fluorescent microscope.

•

All tails are homogenized separately in two set of experiments (12 and 10 at a
time) using liquid nitrogen by individual mortar/pestles to avoid cross
contamination. The homogenized tissue was divided into two tubes, one for RNA
and other for protein.

•

125 ul of 1.5X sample buffer was added to one part of the homogenized tissue
and denatured at 95 c for 10 mins and stored in 4c (later in -80c)

•

700 ul of Trizol reagent added to the other part of tissue to extract RNA. This
trizol added sample can be stored in -80c for long time. Quiagen RNA extraction
was used to get total RNA from tissue. Nude mice tail was used also for RNA
and protein. RNA was eluted with 40 ul buffer and quantified with nanodrop.

•

These RNA was reverse transcribed using oligodT primers and invitrogen
superscript cDNA synthesis kit and both RNA and cDNA was stored in -80C.
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•

We used four primers
– RFP RT primer: (194 bp)
GTC ATC ACC GAG TTC ATG CG,RFP-RT-F,Satadru,25N,,,DSL
ACC TTG GAG CCG TAC TGG AA,RFP-RT-R,Satadru,25N,,,DSL
– GFP RT primer: (165bp)
TGA ACT TCA AGA TCC GCC ACA,eGFP-RT-F,Satadru,25N,,,DSL
TTC TCG TTG GGG TCT TTG CT,eGFP-RT-R,Satadru,25N,,,DSL
– HuKLF8 primer: (156 bp)
CTT TTG GCT AGT GAT TTC AG
AAC AGT AGG AAT GTT TGC TG
– Hu GAPDH primer: (305 bp)
AAC GGG AAG CTC ACT GGC ATG
TCC ACC ACC CTG TTG CTG TAG

•

Rabbit anti RFP antibody (ab34771) ----- 1:2000 in PBST

•

Mouse anti GFP (B-2) antibody (sc9996) ----- 1:1000 in PBST

•

Mouse anti-HA antibody ---------- 1:3000 in PBST

•

Mouse anti-b actin antibody -------- 1:3000 in PBST
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Figure 51. Floxed-KLF8 mice genotyping (western blot with RFP) (Red
shows positive founder mice)

KLF8-gTg mice genotyping

•

Tail Snip of offspring from B65 Tg-Floxed-KLF8 X FVb-Cre mice.

•

Collect genomic DNA, RNA and Protein.

•

Genomic DNA PCR with transgene and loxP specific primer.

•

Western Blot with GFP, RFP, HA, B-actin

•

RT PCR was done with GFP, RFP, HA, GAPDH for the positive mice only

•

We got total 50 pups from different breeding pairs from our first experiment.

•

Genomic DNA genotyping is shown below.

155

FVB-Floxed mice or B65-floxed mice are crossed with FVB-EIIA-Cre mice. As
EIIA-Cre mice are homozygous; the offspring includes KLF8-gTg and Cre control
mice. After tail snips are collected, genomic DNA is extracted by ‘dirty prep’ and PCR is
done with pTg-K8 primers to check for the presence of KLF8 transgene. As the Cre
mice are homozygous, all the offspring mice will carry Cre transgene and thus we don’t
have to check presence of Cre transgene. The mice with both KLF8 and Cre transgene
are KLF8-gTg mice and the mice with only Cre transgene are Cre control mice. The
primer pairs used to genotype KLF8-gTg mice are –
pTg-K8-F (5’-TTC GGC TTC TGG CGT GTG ACC-3’)
PTg-K8-R (5’-TGG CAT CCA GGA GTG TTG GAG-3’)
The pTg-K8 forward and reverse primer will give rise to an amplification of 450 bp after
Cre recombination.

WT -

- -

-

-

-

+

+

- +

Figure 52. KLF8-gTg mice genomic DNA PCR for genotyping
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KLF8-hTg mice genotyping
FVB-Floxed mice are crossed with B6-Myh6-Cre mice. B6-Myh6-Cre mice are
heterozygous which leads to four type of offspring including mixed strain KLF8-hTg,
Floxed control, Cre control and WT control mice. As we are detecting the genotype from
tail snip DNA, we have to investigate presence of both KLF8 transgene and Cre
transgene. Mice with both of them will be KLF8-hTg. Mice with only KLF8 transgene will
be our floxed control. Mice with only Cre transgene will be our Cre control and mice
without any of these two transgenes will be our WT control. As in tail DNA the Cre won’t
express, keeping the floxed transgene intact, we checked for presence of RFP as
indicator of KLF8 transgene.

For presence of KLF8 transgene -- RFP-RT-F 5’-GTC ATC ACC GAG TTC ATG CG-3’
 RFP-RT-R 5’-ACC TTG GAG CCG TAC TGG AA- 3’

These primer pair will detect 200 bp amplification and positive will indicate presence of
KLF8 transgene.

For presence of Cre transgene –
 oIMR1084 - F
 oIMR1085 - R

-

GCG GTC TGG CAG TAA AAA CTA TC
GTG AAA CAG CAT TGC TGT CAC TT

These primer pair will detect 100 bp amplification and positive will indicate presence of
Cre transgene.
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Figure 53. KLF8-hTg mice genomic DNA PCR for genotyping
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Ultrasound Echocardiograph and hemodynamic analysis

Materials
1. Vevo 3100 Imaging Platform with MX550D transducer
2. Aquasonic clear ultrasound gel

3. Signagel electrode gel

4. Aquagel lubricating gel

5. Hair shaving cream

6. ddH20 and paper towel cut into small square pieces.
7. Sterilized cotton buds.
8. Tape to restrain the mouse.
9. PV-15 spray to wipe the bench after the procedure.
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10. PI spray to clean the image platform.

Procedures
Starting up the Vevo 3100 machine:
The Visual Sonics VEVO 3100 echocardiography machine is turned on first along
with the oxygen generator to ensure the oxygen supply.
o Starting Up and Shutting down the System before you power up the Vevo
3100 Imaging System, ensure that the AC power cord is plugged into the
wall outlet using the proper plug, and that the main power switch on the
back (red circled in left image) of the bottom of the system base is turned
ON. The power button (red circled on the right image) is then turned on to
start the computer.

Figure 54. Vevo 3100 ultrasound
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The ultrasound gel warmer is turned on before to pre-warm the gel. The heart
rate monitor is also turned on. Mouse handling pad is warmed and maintained in
37c throughout the procedure.

Preparation of the mice
Mice are anesthetized with isoflurane (1.5-2%). The isoflurane chamber as
shown below has two outlets; one going into the imaging platform and other
going into mouse anesthesia chamber. This outlet lines have regulatory switch
on them. It is turned on when the switch is parallel to the line and turned off when
it is rotated to vertical position. The isoflurane level can be regulated by the nob
(red arrow on isoflurane chamber image). Make sure the oxygen level (black
arrow) is between 1-2.

Figure 55. Isoflurane chamber
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First the mouse of interest is put into anesthesia chamber after turning outlet to
this chamber on. After 3-4 minutes the mouse can be transferred to the image
platform.

Figure 56. Mouse anesthesia chamber

Before transferring the mouse to the imaging platform, the isoflurane outlet to the
platform is turned on and outlet to the chamber is turned off. Make sure both the
outlet is not turned off at the same time which may harm the machine. The
anesthetized mouse is then secured to the imaging platform in supine position
with its nose covered by a cone with constant supply of 1-2% isoflurane to
maintain anesthesia.

Mouse paws are secured to the electrode pads with conductive gel (SIGNAGEL®
Electrode Gel – Parkers Laboratories) and tape to assess ECG. A rectal probe is

162

inserted into mouse anus with Aquagel lubricating gel to overall ensure 37c body
temperature and respiration rate for physiological assessment during imaging.

Depilatory (hair shaving) crème is applied on the mouse chest and upper
abdomen area for couple of minutes. All hair in those areas is removed by
sterilized cotton buds and further cleaned with water soaked paper towels to
remove any trace of remaining hair.

Ultrasound echocardiograph Imaging:

Pre-warmed

ultrasound

gel (Aquasonic clear ultrasound gel

–

parker

Laboratories) is applied on the mouse chest and cotton buds are used to get rid
of the bubbles. MX550D transducer (ultrasound probe) of the Visual Sonics
VEVO 3100 echocardiography machine is moved gently on the mouse chest with
gentle pressure to find the long axis view of LV.

Before starting to take image, Log in, or use the Guest button. Choose an
application from the transducer panel (cardiology for mouse).

After selecting the application; start a new study by selecting “new study”. Series
comes under a study. For example “KLF8-hTg 1 month” is a study and under that
individual mouse will come as individual series. You can change the Study or
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Series name, or add information to the Study or Series by going to the Study
Browser.

VEVO 3100 machine is used to record both B mode and M mode images of the
left ventricle in long axis region and then the probe is rotated right side around
90o to obtain the parasternal short axis view of LV. The M mode images are used
for measurements analysis. The first image must be inverted selecting the ‘left’
button on the screen to always get the apex of the heart on your left hand side.
The transducer has a notch on one of its side. The notch is denoted by a blue dot
on the screen which helps to identify the direction of the image.

Refine your image using the various control panel controls such as Image Depth,
Gain and Orientation.

Tap Freeze to stop the data acquisition. This mode will save a snapshot of the
current view.

Tap Save Clip to save the clip in the buffer. Save clip will save the time frame
video which is required for analysis later on.

Slide the “Slide to Scan” control to resume the data acquisition.
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Continue imaging and use Freeze and Save Clip as required. You can also save
during scanning using Save Clip.

Tap the Current Series navigation button to view all your saved images for the
current series. You can also see these images in the Study Browser.

After B-mode image is captured, start M mode imaging. In M mode, you have to
place the line on the heart (the widest width) and press start on the screen and
save the image with save clip and freeze.

Overall, first capture both B mode and M mode images for the long axis view of
heart and then move the transducer 90 degree on the right side to get short axis
view. Capture B mode and M mode images of short axis of heart. Both axis M
mode images are analyzed later to investigate cardiac function.

A

B

Apex should be on
the left hand side
(After inverting)

Figure 57. Long axis imaging; B mode (A) and M mode (B)
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A

B

Figure 58. Short axis Imaging; B mode (A) and M mode (B)

After recording all the images, the mouse is cleaned with a sterilized wipe soaked
with water and returned to its cage. The cage is kept on a heating pad to help the
mouse regain consciousness. The mouse is monitored following few days to
ensure no side effects of this procedure.

To copy the acquired date, tap the Export button from the Study Browser. Here,
you can: Export To Vevo LAB to export your whole study for further analysis by
vevo software (upstairs) and/or export to other file types to export clips, images,
and other file formats. Shut down the machine after the procedures by pressing
the top right button mentioned before and finally turn off the main power button
on the back of the machine.

Clean the transducer with a normal wipe and put it back the 3100 machine.
Clean the image platform with PI spray. Turn off the oxygen generator,
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isoflurane, gel warmer and heart rate monitor. Clean the imaging station with PI
spray. Clean everything else with accel wipes or PV-15 spray.

Bio-Luminescent Imaging (BLI)

Materials
1. Xenogen IVIS 50 imaging instrument.
2. D-Luciferin (30mg/ml stock_ dilution method is described in the procedure)
3. Syringe
4. Mouse opthalmic ointment

5. Hair shaving cream (Nair) and sterilized cotton buds
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Procedures
Preparation of D-luciferin stock
D-Luciferin is light sensitive and kept in -20C for long term storage. 30 mg/ml DLuciferin stock is prepared beforehand and stored in -20C after aliquoting into small
tubes. To prepare this working stock, D-Luciferin (gold biotechnology) is thawed at room
temperature and dissolved in DPBS to a final concentration of 30 mg/mL (0.3gm of Dluciferin in 10 ml of PBS). After completely dissolving the substrate (1-2hrs in room
temperature), the D-luciferin solution is sterilized through 0.22 µm filter and aliquoted
into small tubes to prevent freeze-thaw cycles. Always wrap the d-luciferin tubes with
aluminum foil during preparation and storage to protect from light. Before imaging, take
out required amount of D-luciferin (30mg/ml) and thaw on ice approximately for 1 hr.

Starting up the IVIS 50
1. The IVIS 50 instrument is always turned on. There are two gas buttons (as showed in
the pic below with two arrows). Turn both of them on first and start the oxygen generator
(wait for green light to be stable).
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Figure 59. Xenoxen IVIS 50

2. The computer associated with IVIS50 is also always turned on. First start the Living
Image® 2.5 software program from the desktop. A system control panel will appear in
the lower right corner of the monitor.

3. Click the Initialize IVIS system button in the camera control panel. After initialization,
the Temperature Status box in the center of the panel should be green, indicating that
the CCD camera is adequately cooled.
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Figure 60. IVIS 50 software startup

Preparation of mice:
1. There are two flip switches on the anesthesia controller; one of them (the right most
one_5 in the image) controls oxygen and isoflurane flow to the anesthesia chamber and
the other one (the middle_4 in the image) controls flow towards the IVIS machine. It is in
‘On’ position when flipped up (parallel to the floor) and in ‘Close’ position when flipped
down (Perpendicular to the floor). Avoid switching on the ‘Evacuation switch’ (1 in the
image) on the left hand side of the panel as it can kill the mice during imaging. Control
oxygen and isoflurane flow by the middle and right switch as desired. Also make sure
the oxygen level for the anesthesia chamber is around 2 and for the IVIS chamber is
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around 1. It can be increased and decreased by turning the nob associated with the
level indicator.
2. The mice were anaesthetized using isoflurane (1.5-2%). The mouse of interest is kept
in the anesthesia chamber first. Make sure that the regulator to anesthesia chamber (no
5) is turned on and regulator to IVIS (switch 4) is in off position. 3 mice can be
anesthetized together. After putting the mice in the anesthesia chamber, D-luciferin is
filled in syringe for IP injection.
Evacuation pump (never use)
1. Gas turn on/ turn off switch
2. Isoflurane regulator
3. Isoflurane and oxygen outflow
regulator to IVIS chamber
4. Isoflurane and oxygen outflow
regulator to anesthesia chamber
(Both these regulator are shown
in turned off position in this
image. It is turned on when
parallel to the floor.
5. Anesthesia chamber
Figure 61. Isoflurane chamber

3. Mice were then injected intraperitoneally with D-Luciferin in phosphate buffer (150
mg/kg mouse weight = (5 * Body weight) ul of 30mg/ml D-luciferin stock) and kept in the
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anesthesia chamber for 8-10 minutes to let the substrate circulate throughout the
mouse body. Mice hair is removed from the area of interest during this time (similarly as
in ultrasound procedure).

4. After 10 minutes, apply ophthalmic ointment ointment to the mouse eyes to protect
them from UV light during imaging.

Imaging

1. Turn on the isoflurane regulator to IVIS (switch 4 in the image) and turn off the
regulator to anesthesia chamber. Place the mouse to be imaged in the center of the
stage in the imaging chamber. Close the door. Make sure that the mouse nose is inside
the anesthesia cone. Avoid switching on the ‘Evacuation switch’ on the left hand side of
the panel as it can kill the mice during imaging.

2. Check the Overlay box in the control panel and set the Exposure Time desired for the
luminescent image. We use 2-3 minutes for this luminescent imaging. Also make sure
that the photographic image is also checked to get the overlay image.

3. Click the Acquire button on the control panel.
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4. After the exposure is complete, the overlaid image is displayed. Edit the information
in the Change Information window and click ‘Done’.

5. Similarly capture the fluorescence image by selecting fluorescence and photographic
image capture method. We use 1 min for this image. For RFP imaging, select DSRed in
both excitation and emission channels and for GFP imaging select GFP. Fluorescence
imaging in IVIS 50 is not that reliable.

6. After all the required image is captured, save the images by clicking ‘Save Graphics’
from ‘File’. It will have options to save the image as JPEG or TIF format. Save it in
desired format (mostly JPEG) to the desired location. A message will prompt asking if
you want to save the data when you try to close the image after saving it in JPEG
format. Click ‘Yes’ and save the file for later analysis. You can also save by choosing
Save Living Image Data under the Living Image menu item to save the displayed data.

7. Keep the mice on heat pad to regain consciousness and monitor regularly for any
detrimental effect.

8. Clean the anesthesia chamber and IVIS machine with Accel wipes. Turn off the
oxygen pump and wait for few minutes before turning off the gas buttons to close
positions. Flip down the anesthesia control buttons.
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9. Close the Living image software. It will take 5 minutes to close. Leave the machine
and computer on and return the mouse to room 146.

10. Fill the isoflurane to the bottom of the triangle mark in the isoflurane chamber.
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